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Parenteral Nutrition-Associated Liver Complications in
Children
Imad F. Btaiche, Pharm.D., and Nabil Khalidi, Pharm.D.
Parenteral nutrition is a life-saving therapy for patients with intestinal failure.
It may be associated with transient elevations of liver enzyme concentrations,
which return to normal after parenteral nutrition is discontinued.  Prolonged
parenteral nutrition is associated with complications affecting the
hepatobiliary system, such as cholelithiasis, cholestasis, and steatosis.  The
most common of these is parenteral nutrition-associated cholestasis (PNAC),
which may occur in children and may progress to liver failure.  The
pathophysiology of PNAC is poorly understood, and the etiology is
multifactorial.  Risk factors include prematurity, long duration of parenteral
nutrition, sepsis, lack of bowel motility, and short bowel syndrome.  Possible
etiologies include excessive caloric administration, parenteral nutrition
components, and nutritional deficiencies.  Several measures can be
undertaken to prevent PNAC, such as avoiding overfeeding, providing a
balanced source of energy, weaning parenteral nutrition, starting enteral
feeding, and avoiding sepsis.
(Pharmacotherapy 2002;22(2):188–211)
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Summary
Parenteral nutrition is the administration of
complete and balanced nutrition, given when
feeding into the gastrointestinal tract is
contraindicated or inadequate.  A commonly
reported complication of parenteral nutrition is
transient elevation of liver enzyme concen-
trations, which return to normal after parenteral
nutrition is discontinued.1, 2 Complications
affecting the liver and biliary system may occur
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with prolonged parenteral nutrition and include
cholelithiasis, cholestasis, and steatosis.  Whereas
steatosis is relatively more common in adults,
cholestasis is the most common and predictable
parenteral nutrition-associated hepatobiliary
dysfunction in children.3–5 In some patients it
may progress to cirrhosis, liver failure, and
death.6
Frequency
The frequency of parenteral nutrition-
associated liver complications varies in studies
from 7.4–84%.  In follow-up studies, complications
occurred in 40–60% of children who required
long-term parenteral nutrition.4 Variation in
reported frequency is due to differences in study
populations (premature vs term infants or older
children), definition of liver dysfunction (based
on biochemical or histologic values), composition
of parenteral nutrition solutions, duration of
parenteral nutrition administration, and
underlying medical or surgical conditions in
study subjects.  In one study, approximately 30%
of mostly premature infants had elevated liver
enzyme concentrations after receiving parenteral
nutrition for 2 weeks.2 Liver enzyme
concentrations were elevated in 53% of children
after 4 weeks of parenteral nutrition.  Patients
with short bowel syndrome who require a longer
duration of parenteral nutrition have a higher
frequency of liver complications.  Liver
dysfunction occurred in 67% of children with
short bowel syndrome who received parenteral
nutrition for a mean duration of 16.5 weeks,
compared with 30% of children with normal
bowel length who received parenteral nutrition
for a mean duration of 6 weeks.7 Liver
dysfunction, mainly cholestasis, was reported in
65% of parenteral nutrition-dependent infants
with short bowel syndrome.8
The reported frequency of parenteral nutrition-
associated cholestasis (PNAC) also varies among
studies.  In a retrospective review of medical
records of neonates who received parenteral
nutrition for at least 1 week, 15% of infants
developed PNAC, (serum conjugated bilirubin
concentrations ‡ 2 mg/dl).9 In another study, the
overall frequency of PNAC (serum conjugated
bilirubin concentrations ‡ 2 mg/dl) was 43% in
infants who received parenteral nutrition for
19–75 days (mean ± SEM 49.6 ± 7 days) and 67%
in premature infants.10 The disorder occurred in
23% of premature infants (serum conjugated
bilirubin concentrations ‡ 1.5 mg/dl) after a
mean parenteral nutrition duration of 42 days.11
Clinical Features
Transient elevation of liver enzyme
concentrations may be observed early in the
course of parenteral nutrition without denoting
significant liver dysfunction.12 However, with
prolonged parenteral nutrition, liver dysfunction
may be severe and may progress to liver failure.13
As liver dysfunction progresses, patients may
have hepatomegaly, splenomegaly, ascites, and
varices.  Cholestasis typically is associated with
elevated serum bilirubin concentrations in the
presence or absence of jaundice depending on
the severity of the cholestasis.  Progressive
elevation in serum bilirubin concentrations in
association with persistent jaundice usually
denotes a risk for high mortality.14, 15 Mortality
was as high as 31% in surgical neonates with
PNAC, compared with 3% in neonates without
PNAC.16 In a study that assessed children with
PNAC for bowel and/or liver transplantation, the
main risk factors for death were the presence of
cirrhosis, splenomegaly, and serum bilirubin
concentrations above 5.84 mg/dl.17
Biochemical Markers
Elevation of liver enzyme concentrations is the
earliest marker of liver dysfunction.  The time to
onset of dysfunction after starting parenteral
nutrition is difficult to predict and varies with the
presence or absence of risk factors.18 In infants
with PNAC, elevations in serum alkaline phos-
phatase, bilirubin, and g-glutamyl transpeptidase
(GGT) are the most common biochemical
abnormalities.  Serum aspartate aminotransferase
(AST) and alanine aminotransferase (ALT)
concentrations also may be elevated,2, 14, 18–20 but
usually after onset of cholestasis or jaundice.16, 21
Serum conjugated bilirubin, alkaline phos-
phatase, and AST concentrations were elevated
after 2.2 ± 0.2, 4 ± 0.8, and 4.6 ± 0.7 weeks of
parenteral nutrition therapy, respectively.  The
values returned to normal within 1–4 months
after parenteral nutrition was discontinued.2
Serum conjugated bilirubin concentrations
typically return to normal within 1 week–2
months.10, 11 In the absence of irreversible
hepatic damage, complete liver recovery is
expected,1 although liver biopsies may show
subtle abnormalities for months after parenteral
nutrition is stopped.22
Serum bile acid concentrations were proposed
to be markers that correlate with the degree of
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histologic liver changes.23–26 Elevations in these
concentrations may be either the result of
regurgitation of bile acids from the hepatocytes
into the blood,23, 26, 27 or a reflection of
immaturity of hepatic excretory functions in
premature infants.28 Because a reference range
for these concentrations in infants is difficult to
establish due to changes in bile synthesis and
transport,29 and since other sensitive biochemical
values are simpler to measure, monitoring serum
bile acid in patients with PNAC is not a routine
practice.
Serum GGT and conjugated bilirubin
concentrations are considered the most sensitive
indicators of cholestasis.11, 18, 27 Both can be
elevated as early as 1 week in infants with
PNAC.12
g-Glutamyl transpeptidase is an enzyme that is
widely distributed in the body with prominent
activity in the kidneys, pancreas, and liver.  In
the liver, it is present in periportal hepatocytes,
bile canaliculi, and biliary epithelial cells.
Despite GGT’s sensitivity for hepatobiliary
disease, serum GGT concentrations lack
specificity because levels may be elevated in
other diseases.30, 31 This lack of specificity32
makes GGT most useful as an indicator of
cholestasis when measured in combination with
other variables, such as to confirm the
hepatobiliary origin of elevated alkaline
phosphatase levels.33 Although alkaline
phosphatase is a sensitive marker for bile
obstruction, its increased activity during bone
formation in children10, 21 or as a result of
neonatal metabolic bone disease34 makes it a less
specific indicator of cholestasis in the growing
child.
Since elevated serum conjugated bilirubin
concentrations reflect a reduction in bile flow,
they are considered the prime marker for
cholestasis.21, 35 Clinical studies define PNAC as
when the bilirubin concentrations are at least 1.5
mg/dl.9–11, 16, 36–38 In clinical practice, the most
established  concentration is 2 mg/dl or greater.
The extent and duration of elevation may predict
severity and mortality in patients with parenteral
nutrition-associated liver dysfunction.13, 17, 38
Histopathology
Histologic liver studies in patients with
parenteral nutrition-associated hepatobiliary
dysfunction may reveal a wide spectrum of
pathologic features, including canalicular and
intralobular cholestasis, periportal inflammation,
bile duct proliferation, pseudoacinar formation,
portal-portal bridging, steatosis, portal fibrosis,
and cirrhosis.2, 14, 18 In evaluating children with
advanced PNAC for small bowel or small bowel
and liver transplantation, the frequencies of
specific histologic abnormalities were as follows:
portal fibrosis 100%, pericellular fibrosis 95%,
bile duct proliferation 90%, portal bridging 86%,
pigmented Kupffer cells 81%, portal inflam-
mation 76%, pseudoacinar formation 71%,
cirrhosis 48%, and steatosis 43%.17
Risk Factors
The following risk factors predispose to liver
complications in patients receiving parenteral
nutrition:  prematurity and low birthweight,10, 11,
39 long duration of parenteral nutrition,7, 9, 11, 16, 37,
40–42 sepsis,23, 39 bowel rest and lack of enteral
feeding,9, 18, 41, 43 and short bowel syndrome.15, 42, 44
Prematurity
Premature infants are born before 38 weeks’
gestational age with birthweight below 2500 g
depending on degree of prematurity.  They are at
great risk for PNAC11, 39 due to physiologic
immaturity of their hepatic excretory systems.10,
11, 28, 45, 46 The lower the gestational age, the
higher the elevation in serum bilirubin
concentrations39 and the more rapid and severe
the development of PNAC and jaundice.40 In one
study, the overall frequency of PNAC was 50% in
premature infants with a birthweight below 2000
g.  Fifty percent of infants weighing less than
1000 g developed PNAC compared with 7% of
infants with a birthweight above 1500 g.11 The
frequency increased from 1.4% to 5.3% to 13.7%
in infants who were born at over 36 weeks’,
between 32 and 36 weeks’, and before 32 weeks’
gestation, respectively.40
Duration of Parenteral Nutrition
The frequency of liver dysfunction and
cholestasis increases with prolonged parenteral
nutrition administration.7, 9, 11, 16, 40 After mean
duration of 42.6 and 115.7 days, liver
dysfunction occurred in 30% and 67% of
children, respectively.7 Overall, PNAC occurred
in 35% of surgical neonates who received
parenteral nutrition for at least 2 weeks, and
increased to 58% and 75% after parenteral
nutrition was given for at least 30 and 90 days,
respectively.  All neonates who received
parenteral nutrition for more than 180 days
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developed cholestasis.16
In a retrospective review of the medical records
of 172 neonates who received parenteral
nutrition for at least 1 week, a direct correlation
was seen between severity of cholestatic jaundice
and duration of parenteral nutrition.  Neonates
who received parenteral nutrition for 1–6 weeks,
7–10 weeks, and more than 11 weeks had
progressive elevations of mean serum conjugated
bilirubin concentrations corresponding to 4.21 ±
1.63, 4.91 ± 1.44, and 5.56 ± 1.61 mg/dl,
respectively.9
Because of the direct correlation between
duration of parenteral nutrition and liver toxicity,
parenteral nutrition should be given for the
shortest possible time.  In addition, oral or
enteral feeding, even in partial amounts, should
begin as soon as clinically feasible.41, 42
Sepsis
Sepsis is a common complication of the
infusion of parenteral nutrition in children.47 It
may cause cholestasis, but bile stasis, in turn,
may increase septic rate.  In a study that included
surgical neonates, sepsis was observed in 56% of
infants with PNAC compared with 13% of those
with normal serum bilirubin concentrations
(p<0.05).  It was reported in 78% of infants
before the onset of jaundice.16
Sepsis as a Cause of Cholestasis
Although the source of blood infections in
patients receiving parenteral nutrition is usually
microbial migration along the venous catheter,
bacteremia may be the result of bacterial
translocation from the gut into the blood-
stream.48–50 Gram-negative bacterial infections,
especially with Escherichia coli, were associated
with hyperbilirubinemia51 and jaundice16 in
children.  Jaundice resolved and liver enzyme
concentrations returned to normal after
treatment with systemic antibiotics.50, 52–55 In an
analysis of risk factors leading to PNAC, surgical
neonates had a 30% increase in plasma bilirubin
concentrations during recurrent episodes of
sepsis.39 Other liver enzymes including AST,
ALT, lactate dehydrogenase,48, 56 and alkaline
phosphatase57 also may increase during sepsis.
At the hepatocellular level, liver biopsies of
infants who developed jaundice after bacterial
sepsis had hepatocellular alterations,
intracanalicular and intracellular cholestasis, bile
stasis, and bile duct proliferation.58
The mechanism of sepsis-induced cholestasis is
unknown, but research has focused on the
possible toxic effects of endotoxins or
lipopolysaccharides on the hepatobiliary system.
Endotoxins are released from the outer
membrane of gram-negative bacteria during
systemic infections, or may translocate from the
gut into the portal circulation by binding to
specific sites of the intestinal membrane after
their release by enteral bacteria.59 After reaching
the liver, the amount of endotoxins may exceed
the ability of Kupffer cells to detoxify them,60
thus leading to their sequestration in
hepatocytes59, 61 and causing direct hepatocellular
injury.  At the hepatocellular level, endotoxins
may cause cholestasis by inhibiting the Na+-K+-
adenosine triphosphatase (ATPase) pump in
parenchymal liver cells.62 Indirectly, they may
mediate the formation of cytotoxic bile acids,63 or
stimulate the release of hepatotoxic inflammatory
cytokines such as tumor necrosis factor (TNF)
and interleukins 1 and 6,64–66 which all are
thought to be hepatotoxic mediators.
Endotoxins may alter hepatic excretory
functions,67, 68 induce giant cell transformation of
the liver and hepatocyte necrosis,69 and impair
bile flow in a dose-dependent manner.61 In an
animal experiment that showed a possible role of
endotoxins in cholestasis, rats injected with
human serum from a patient with PNAC
developed a similar cholestatic picture to the one
seen in that patient.  Rats had improved bile flow
after they were injected with antibodies to the
endotoxin isolated from sequestered E. coli in
that patient.68
Tumor necrosis factor is a protein released by
macrophages in response to endotoxin stimuli.
Supporting evidence about its hepatotoxic effects
comes from improvement in liver injury after
administration of TNF antibodies to rats fed
parenteral nutrition.70 On the other hand, the
administration of polymyxin B, an effective
antibacterial against gram-negative bacteria,
blocked endotoxin activity and consequently
TNF production, and led to improvement in
steatosis in rats.71 These observations coupled
with a report that TNF could stimulate hepatic
lipid synthesis72 led investigators to hypothesize
that TNF is hepatotoxic and could be a cause of
steatosis as well as cholestasis during sepsis.70, 73
Besides their effects on the liver, endotoxins
may increase intestinal permeability,74, 75 diminish
immunologic defense mechanisms, and alter host
response to infection.76 Administration of
endotoxins to laboratory animals increased
intestinal permeability to enteric bacteria and
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contributed to bacterial translocation.77 Also,
atrophy of gut-associated lymphatic tissue,78
physical disruption of the intestinal barrier,
bacterial overgrowth, and impaired gut or host
defense mechanisms would facilitate bacterial
translocation.75, 79, 80
Effects of Bile Stasis on Sepsis
Bile stasis may predispose to sepsis,81-83
possibly by impairing cell-mediated immunity.84
Sepsis occurred in 80% of infants with PNAC
compared with 29% of infants without
cholestasis (p=0.006).82 Although a high
frequency of sepsis was reported in patients with
PNAC, further studies are necessary to clarify the
effects of cholestasis on sepsis.
Since a strong correlation exists between
cholestasis and sepsis, control measures should
be undertaken to prevent infections from
developing in patients receiving parenteral
nutrition.  Meticulous catheter care, aseptic
handling of parenteral nutrition infusion, and
aggressive treatment of intercurrent infections are
recommended to minimize the effects of sepsis
on the liver in patients who are dependent on
parenteral nutrition over the long term.
Bowel Rest
Figure 1 illlustrates the possible effects of
bowel rest on the pathophysiology of PNAC.
Bowel Rest and Bile Acids
Secretion of bile acids in the intestines is
increased by meals and decreased by fasting.  As
a consequence of fasting, a decrease in
canalicular bile flow causes bile acids to
sequester in the gallbladder.  On the other hand,
hypertonicity of the parenteral nutrition solution
may induce shrinkage of hepatocytes, reductions
in bile volume and flow, and decreased transport
of conjugated bile acids.85 Thus, PNAC may be
the result of reduced bile flow and altered bile
acid metabolism.86 As a result, accumulation of
bile acids in the gallbladder will cause
precipitation of cholesterol and calcium
bilirubinate in bile ducts, leading to cholestasis
and gallstone formation.85 In support of this
theory, hyperviscous and tenacious bile was
recovered from patients during surgical biliary
irrigation to relieve refractory PNAC.87, 88 Biliary
sludge or stones also were seen in many
patients.88
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Figure 1. Suggested effects of bowel rest on the pathophysiology of parenteral nutrition-associated cholestasis.  CCK =
cholecystokinin; TNF = tumor necrosis factor; IL = interleukins.
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The proposed effects of various bile acids in the
pathophysiology of hepatobiliary complications
require further elucidation.  The two primary bile
acids are cholic acid (CA) and chenodeoxycholic
acid (CDCA).  They are produced in the liver
from cholesterol and then conjugated with
taurine or glycine.  Cholic acid and CDCA also
are metabolized by intestinal bacteria to form the
secondary bile acids deoxycholic acid (DCA) and
lithocholic acid (LCA), respectively.  Normally,
biliary bile acids in humans contain a small
fraction of ursodeoxycholic acid (UDCA; < 5%)
and LCA (< 5%), whereas CA, CDCA, and DCA
constitute more than 90% of the overall bile acid
pool.85, 89 Contrary to LCA and CA, UDCA
appears to be nonhepatotoxic due to its
hydrophilicity and its lower surface activity.  In
animal studies LCA induced common bile duct
hyperplasia and gallstones formation90 and CA
caused biliary fibrosis.91 In addition, elevated
LCA concentrations in bile and serum of patients
with PNAC24, 63 and similarities between hepatic
lesions in humans with PNAC and animals that
were given LCA suggest a role of LCA in causing
liver injury.63
Administration of UDCA and enteral feeding
have protective effects on the liver.
Administration of UDCA improves clinical signs
and symptoms of cholestasis,92–94 possibly by
displacing cytotoxic bile acids.  Because bile acid
secretion is proportional to oral intake,85 early
start of oral or enteral feeding restores
enterohepatic circulation of bile acids and
prevents accumulation of toxic bile acids in the
hepatobiliary system.
Bowel Rest and Gut Hormones
The presence of food in the intestines causes
stimulation and release of intestinal enzymes and
hormones that help maintain physiologic balance
between the gastrointestinal and hepatobiliary
systems.95 Cholecystokinin (CCK) is a peptide
hormone that is secreted in the duodenum in
response to food, namely, enteral fat and
proteins.96 It causes gallbladder contraction,
relaxes the sphincter of Oddi, increases bile
flow,43 and stimulates intestinal motility.97 By
improving gut motility, CCK may prevent
bacterial overgrowth and reduce bacterial
translocation.97
Reduced blood concentrations of intestinal
hormones and gut peptides were seen in
premature infants who were parenteral nutrition
dependent compared with enterally fed infants.98
As a result of lack of CCK during bowel rest,
gallbladder contractility is reduced, which could
lead to bile stasis.  For instance, ultrasonographic
studies showed significantly more gallbladder
distention in infants who received parenteral
nutrition than in those who received enteral
feeding (p=0.0001).  Also, none of the infants in
the parenteral nutrition group had gallbladder
contractions.99 On the other hand, infants with
PNAC who were given exogenous intravenous
CCK had a decrease in hyperbilirubinemia and
improvement in clinical signs of cholestasis.100, 101
Thus, reduced CCK secretion during bowel rest
may play a role in the pathophysiology of
cholestasis.  As such, exogenous administration
of synthetic CCK has been investigated for its
possible role in preventing PNAC.
Bowel Rest and Bacterial Translocation
The gastrointestinal tract serves as a protective
barrier to prevent intraluminal bacteria and
toxins from reaching systemic organs.75 This
barrier may become disrupted as a consequence
of bowel rest.  Lack of intestinal motility leads to
atrophy of the small bowel cellular lining,
disrupts the normal balance of intestinal
microflora,75, 102 and promotes bacterial
overgrowth that by itself may damage the
intestinal barrier.67, 103 In addition to these
effects, bowel rest leads to reduced intestinal
immunity,67 decreased intestinal immunoglobulin
A (IgA) levels,104 and enhanced production of
hepatotoxic cytokines.76, 105
As a result of increased gut permeability,
bacterial translocation may occur.  This describes
the passage of intestinal microflora from
intestines into the mesenteric lymph nodes,
blood, or organs such as liver and spleen.78, 106
Bacterial translocation has detrimental effects on
the liver similar to the effects of sepsis, bacterial
endotoxins, and cytokines.107
A few human reports focused on bacterial
translocation in parenteral nutrition-dependent
patients.48, 49 A significant correlation was found
between bacterial overgrowth and cholestasis41
and between bacterial overgrowth and prolonga-
tion of parenteral nutrition dependence.108
Intestinal microbial overgrowth was seen in 64%
of infants receiving parenteral nutrition who later
developed sepsis with the same microorganisms
isolated from blood and gastrointestinal tract.
Isolated microorganisms were E. coli, Klebsiella,
enterococci, and Candida sp.48
Based on these observations, investigators
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suggested that a disruption in the intestinal
barrier leads to bacterial translocation to the liver
with subsequent release of endotoxins that cause
liver damage.  Introducing enteral feeding should
restore intestinal motility and prevent bacterial
translocation.  Bacterial overgrowth should be
treated with enteral antibiotics to reduce bacterial
translocation or endotoxin production by
intestinal gram-negative bacteria.
Short Bowel Syndrome
This clinical condition is characterized by
intestinal failure associated with malabsorption
and metabolic abnormalities after extensive
resection of the small intestine.109 Neonates
develop short bowel syndrome secondary to
gastroschisis, intestinal atresia, volvolus, or
severe necrotizing enterocolitis,110 whereas in
older children short bowel syndrome is a
consequence of Crohn’s disease, radiation
enteritis, mesenteric infarction, intestinal tumor,
or trauma.109 Long-term parenteral nutrition is a
life-saving therapy for patients who undergo
massive intestinal resection.110, 111 Long duration
of parenteral nutrition is expected when more
than 75% of small intestine is resected or less than
80–100 cm of small intestine remains.109, 112, 113
Parenteral nutrition-associated hepatic fibrosis,
cholestasis, and liver failure are leading causes of
death in patients with short bowel syndrome.17, 38,
110, 114, 115 In a report that correlated hyper-
bilirubinemia with mortality, serum conjugated
bilirubin concentrations greater than 4 mg/dl for
at least 6 months after the development of short
bowel syndrome resulted in a 78% mortality
(sensitivity 70%, specificity 87%).38
Factors that predispose patients with short
bowel syndrome to liver dysfunction include
reduced intestine length,44 bacterial overgrowth,
long duration of parenteral nutrition,108 and
abnormal bile acid metabolism and excretion
resulting from interruption of the enterohepatic
circulation after ileal resection.85 Of note,
patients with the most severe gastrointestinal
diseases require long duration of parenteral
nutrition and thus are at high risk for sepsis,
among other factors that cause cholestasis.49 A
significant correlation was found between
remaining small bowel length of less than 50 cm
and PNAC,42 with as high as 70% of infants with
short bowel syndrome eventually developing
PNAC.38 In 14 infants with mean residual
jejunoileal length of 16% of normal for
gestational age, PNAC and cholelithiasis
developed in 57% and 21%, respectively; two
infants died of liver failure.116
Several measures should be undertaken to
prevent PNAC in children with short bowel
syndrome, such as early and gradual start of
enteral feeding, treatment of bacterial
overgrowth, and prevention and treatment of
sepsis.117 In addition to maintaining gut integrity,
enteral feeding promotes intestinal adaptation
and minimizes dependence on parenteral
nutrition.109, 118 Unfortunately, patients with
massive small bowel resection require long-term
supplemental or full parenteral nutrition support
and are likely to develop liver failure.  The only
life-saving alternative to indefinite parenteral
nutrition in patients with short bowel syndrome
and advanced liver disease is intestine or
combined intestine-liver transplantation.13, 119, 120
Possible Etiologies
Excessive Calories
Excessive calorie administration (overfeeding)
from combined or individual energy substrates
(amino acids, dextrose, lipids) or an imbalanced
source of energy can contribute to liver
dysfunction.  Jaundice and the histologic features
of PNAC were improved by reducing the total
amount of calories from parenteral nutrition.121
Excessive Dextrose
Although excessive dextrose infusion may lead
to steatosis but not to cholestasis, both conditions
may coexist in patients with parenteral nutrition-
associated liver dysfunction.122 Presumably, the
abnormalities are the result of altered insulin:
glucagon ratio in portal circulation and resultant
hyperinsulinemia that causes glucose to convert
to fat in the liver.123 Although parenteral
nutrition-associated steatosis is reported
primarily in adults and is uncommon in infants,
it should be suspected when hepatomegaly and
elevated serum aminotransferases are present.4
Since excess carbohydrates deposit in the liver as
fat,124 reducing the carbohydrate load should
prevent steatosis.20, 125 In children, carbohydrates
should provide no more than 65% of total
calories,125 and dextrose infusions in infants
should be limited to a rate not exceeding 14
mg/kg/minute, which corresponds to infants’
maximum glucose oxidative capacity.124 Also,
providing a balanced source of calories avoids
liver dysfunction.  Liver steatosis occurred in
53% of patients who received only dextrose
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infusions, compared with 17% of those who
received mixed dextrose and lipid emulsions
(70:30 ratio, respectively, p=0.05).126 Therefore, a
safe and balanced parenteral nutrition regimen
should provide 25–30% of calories from lipids
and 50–60% of calories from dextrose.56, 127-129
Amino Acids
Protein hydrolysates of casein and fibrin were
early sources of parenteral amino acids.  Such
formulations had large amounts of dipeptides,
tripeptides, and ammonia, and variable amounts
of nonessential amino acids.130 These solutions
were associated with hyperammonemia, acidemia,
allergic reactions, and liver dysfunction.131 Later,
standard as well as disease- and age-specific
formulations of crystalline amino acids were
introduced to replace protein hydrolysates.132 Of
these, the specialized pediatric crystalline amino
acid formulation was developed to try and
reproduce a plasma amino acid profile consistent
with that of breastfed infants and to contain a
balanced source of essential and nonessential
amino acids.133 These formulations were better
tolerated and resulted in satisfactory weight gain
and nitrogen retention in children.133–135
Amounts and Types of Amino Acids
The development of PNAC in children may be
linked to both excessive136, 137 and cumulative
amounts of amino acids.138 The disorder also
may be related to the toxicity or deficiency of
certain amino acids, specifically methionine
excess,139 cysteine deficiency,140 and tryptophan
and its degradation products137, 141 that were
suggested as causes of cholestasis.  Several
mechanisms are proposed to explain the
mechanism of amino acid-induced cholestasis,
such as possible alteration in canalicular flow and
membrane permeability142 by a direct effect of
amino acids on the canalicular membrane,27
leading to accumulation of hepatotoxic bile
acids,142, 143 dissipation of the transmembrane
sodium gradient by uptake of sodium-dependent
amino acids that decrease the driving force for
bile acid transport,144 or depletion of hepatic
adenosine triphosphate (ATP) by excess
methionine.145
The notion that amino acids have a tendency
to suppress bile flow and bile salt secretion is
supported by animal studies.142 In studies of rat
liver perfusion, amino acids caused a
concentration-dependent inhibition of bile flow
with high amino acid perfusate concentrations,
causing great reduction in bile flow.146–148 When
parenteral nutrition was given to rabbits
intravenously or orally, bile flow and hepatic
secretory functions became clearly suppressed
compared with rabbits that had chow feeding.
Histologic studies showed that liver injury in
animals was similar to that in humans with
PNAC.149
Although some studies did not support a link
between amino acids and cholestasis,16, 40 others
did.27, 136, 137, 150 Premature infants who received
amino acid-free parenteral nutrition with enteral
whey protein supplementation 2.5–3 g/kg/day
had no signs of PNAC, compared with 58% of
infants who developed PNAC after 3 weeks of
standard parenteral nutrition with amino acids.
However, the investigators were unable to
conclude whether the reduction in cholestasis in
the enterally fed group was due to enteral feeding
or avoidance of parenteral amino acids.151 In a
study that reported two levels of amino acid
intake, infants who received 16% (5.0 ± 0.2
g/kg/day) of calories from amino acids had a
substantial increase in serum alkaline
phosphatase concentrations during the fourth
week of the study compared with infants in
whom amino acids provided 8% (2.7 ± 0.1
g/kg/day) of total calories.  Cholestasis developed
in two of five infants with the higher amino acid
intake.137
In another study that correlated the severity of
PNAC with amount of parenteral amino acids
and duration of parenteral nutrition, preterm
infants who received amino acids (mean ± SEM)
4.2 ± 1.1 g/kg/day developed PNAC, whereas
PNAC was not seen in infants who received
amino acids 1.7 ± 0.5 g/kg/day.  Infants who
received more than 2.5 g/kg/day for more than 4
weeks developed cholestatic jaundice.  As a
result, the investigators suggested that the amino
acid dosage in preterm infants should not exceed
2.5 g/kg/day.150 Similarly, infants who received
parenteral amino acids 3.6 g/kg/day had
significantly higher serum conjugated bilirubin
concentrations than infants who received 2.3
g/kg/day.  The higher dosage was associated with
more severe and earlier onset of cholestatic
jaundice.136
A definite relationship between plasma amino
acid concentrations and liver dysfunction has not
been established.  However, results of available
studies may lead one to conclude that liver
abnormalities with amino acid infusions suggest
possible dose-related toxicity.  Amino acid
dosages that were associated with liver toxicity136,
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137, 150 exceeded the usually recommended
maximum dosage of 3 g/kg/day for parenteral
amino acids in infants.152 Thus, since dosages of
2.5–3 g/kg/day would achieve a positive nitrogen
balance in most infants,152–154 it seems prudent
not to exceed that limit so as to avoid liver
toxicity.
Methionine Toxicity
Animal studies implicated certain free amino
acids, namely methionine, in causing cholestasis149,
155 and steatosis.145 Methionine is an essential
sulfur-containing amino acid that is metabolized
by transsulfuration and transmethylation
pathways, leading to the formation of cysteine,
taurine, and glutathione.  Cystathionase is the
rate-limiting enzyme in the formation of cysteine
from cystathionine, an intermediate in the
metabolism of methionine (Figure 2).139, 156
In animal studies, plasma methionine
concentrations were higher in rabbits that
received parenteral nutrition than in rabbits that
had chow feeding.149 Intravenous methionine
repressed bile flow and reproduced histologic
liver injury in rabbits similar to that observed
with parenteral nutrition.155 A direct correlation
was found between methionine perfusate
concentrations and inhibition of bile flow in
perfused rat liver.146
In humans, blood methionine concentrations
were high in infants receiving parenteral
nutrition135, 140 and in those who died of PNAC
and cirrhosis.157 To date, no human data have
correlated cholestasis to methionine in parenteral
nutrition or to methionine blood concentrations.
Several theories are proposed to explain the
mechanisms behind the potential hepatotoxic
effects of methionine in infants.  Premature
infants are born with a low cystathionase activity,
which reduces their ability to metabolize
methionine to taurine and glutathione
efficiently.45, 158 They also may be unable to
synthesize adequately S-adenosylmethionine,151 a
methyl donor derived from methionine and ATP
(Figure 2).139 Since taurine plays a role in bile
acid conjugation, a deficiency may predispose
these infants to cholestasis.159 In addition,
research focused on the possible role of free
radicals in causing liver injury and the protective
role of the antioxidant glutathione.  Since
premature infants may have low levels of
glutathione as a result of low cystathionase
activity and S-adenosylmethionine deficiency,
they may be at increased risk for liver damage
from free radicals, especially during oxidative
stress.139 On the other hand, S-adenosyl-
methionine deficiency in these patients may
predispose to cholestasis.  In a preliminary study
in rats, S-adenosylmethionine increased bile acid
secretion and maintained bile flow possibly by
maintaining a normal Na+-K+-ATPase plasma
membrane activity.160
Strong human data correlating cholestasis to
methionine in parenteral nutrition are lacking.
Nevertheless, some investigators suggested
lowering methionine concentrations in
crystalline amino acid solutions and providing
alternative substrates for the transsulfuration
pathway to minimize possible toxic effects of
methionine on the liver.139
Lipid Emulsions and Plant Sterols
Lipid Emulsions
Lipid emulsions are a source of calories and
essential fatty acids.  Accumulated evidence
shows that liver dysfunction may occur only with
high dosages of lipid emulsions, and in rare cases
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Figure 2. Methionine metabolism via the transsulfuration
pathway (some intermediates and pathways are omitted for
clarity).  ATP = adenosine triphosphate.
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of essential fatty acid deficiency.  The exact
mechanism of such toxicity is unknown.
A report of patients who developed cholestasis
and hepatic cytolysis after a change in lipid
emulsion formula raised the hypothetical
question whether liver dysfunction could be
related to the size of lipid particles in that
emulsion, lecithin purification process, or
sodium oleate content.161 Based on an in vitro
study, lipid emulsions induce dose-dependent
inhibition of cholesterol uptake by cultured
hepatic cells.  It thus is proposed that reduced
cholesterol availability for bile formation by
hepatocytes would result in decreased bile
volume and reduced bile secretion and flow that
lead to cholestasis.162 Similarly, animal studies
showed that lipid emulsions may cause a
reduction in bile flow163, 164 but without an effect
on serum bile acid concentrations138 or on GGT
levels.164 Also, parenteral nutrition regimens that
incorporated lipid emulsions caused further
exacerbation of hepatic steatosis in rats.164, 165
In humans, the association between lipid
emulsions and liver dysfunction was reported in
adults166 and children.167 In adults, a significant
elevation in serum bilirubin and alkaline
phosphatase concentrations occurred with high
dosages of lipids when dextrose only provided
22% of total calories.  Patients who received a
lower lipid dosage with a balanced calorie
regimen (65% of calories from dextrose, 35%
from lipids) did not show signs of liver
abnormalities.166 In a retrospective review of 10
children with PNAC receiving home parenteral
nutrition, a relationship was suggested between
lipid emulsions and cholestasis.  This led
investigators to suggest giving lipid emulsions 5
days/week at a dosage not exceeding 2–2.5
g/kg/day, with a lipid:energy ratio not exceeding
25%.167
Conversely, other human studies showed a
protective effect of lipid emulsions on the liver
when a balanced nutritional regimen was
provided.  Patients who received lipid-free
parenteral nutrition later developed steatosis as a
result of essential fatty acid deficiency that
resolved with fatty acid supplementation.168, 169
Hepatic accumulation of fat was seen in patients
who received amino acid and carbohydrate
mixture but not in those who received a balanced
parenteral nutrition that provided lipid
emulsions.170 When one-third of carbohydrate
calories was replaced with lipid calories, the
elevation of liver enzyme concentrations was
lower than that with lipid-free parenteral
nutrition.129
Accumulated evidence in humans makes it
unlikely that lipid emulsions in recommended
amounts are a major factor in causing direct
hepatocellular toxicity.18, 171, 172 No statistically
significant differences were found in elevations
from baseline of serum alkaline phosphatase and
AST concentrations when a high lipid (30%
calories as lipid) and low lipid (2.5% calories as
lipid) parenteral nutrition were compared.173 The
emulsions appear safe when given to children at
dosages not exceeding 3 g/kg/day.  In case of
hypertriglyceridemia, the dosage should be
reduced to 0.5–1 g/kg/day to provide enough
linoleic acid to prevent essential fatty acid
deficiency.174 A lipid:energy ratio of 25–30% is
appropriate to provide balanced caloric intake.167,
173
Lipid emulsions in the United States are made
of long-chain triglycerides (LCT) derived from
soybean or soybean-safflower oil.  Considering
the faster oxidation rate of medium-chain
triglycerides (MCT) compared with LCT, early
animal and human data suggest that the MCT-
LCT mixture may be better tolerated and may be
less likely to cause hepatic dysfunction.175 Such a
mixture is available in Europe but is still
investigational in the U.S.
Plant Sterols
Interest in the role of plant sterols in the
pathogenesis of cholestasis increased after high
plasma concentrations of phytosterols were
detected in a 3-year-old boy with PNAC.176
Phytosterols form major plant sterols and are
contaminants of lipid emulsions.  Unlike
cholesterol, they are inefficiently metabolized to
bile acids by the liver.177
It is postulated that phytosterols may impair
the hepatocyte canalicular secretory activity,178
bind to membrane proteins and affect membrane
fluidity and transporters, reduce bile synthesis
and flow, and precipitate in the bile causing
formation of biliary sludge and stones.176 In an
experimental neonatal piglet model, daily
injection of plant sterols for 14 days resulted in
phytosterolemia and decreased bile acid
excretion.  No histologic or clinical signs of
cholestasis were detected.
In a human study of 29 children who had
received lipid emulsions over 2 months, 5
children with severe PNAC (bilirubin > 5.84
mg/dl, AST > 200 U/L) had high plasma
concentrations of phytosterols (campesterol,
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stigmasterol, sitosterol, isofucosterol, sitostanol,
cholestanol) similar to that seen in hereditary
phytosterolemia.179 Children with less severe
PNAC had lower concentrations.  All plant
sterols in the plasma were present in the lipid
emulsion.  All five patients had decreased plasma
phytosterol concentrations with reduction or
discontinuation of lipid emulsions; however, only
three had improvement in liver function tests.  Of
note, lipid dosages were higher in the group with
severe PNAC than in the group with mild PNAC.
Based on available studies, no convincing data
allow a definite correlation between phytosterols
and cholestasis in patients receiving lipid
emulsions.  Further studies are required to
explain whether an association exists between
plasma phytosterol concentrations and liver
dysfunction.
Manganese Toxicity
Manganese is a trace mineral that is
supplemented daily to parenteral nutrition
solutions in accordance with recommendations
of the American Medical Association and the
American Society for Clinical Nutrition.  It is
primarily eliminated in the bile and may
accumulate in patients with cholestasis.  High
plasma manganese concentrations were reported
in patients who had cholestasis while receiving
parenteral nutrition.180 Neurotoxicity is the most
frequent toxicity with hypermanganesemia that
was reported in patients receiving long-term
parenteral nutrition7, 181–184 and in those with
cholestasis.185
In a group of 57 children receiving parenteral
nutrition for longer than 2 weeks, 11 had both
cholestasis and hypermanganesemia.186 A
significant correlation was found among whole
blood manganese concentrations, plasma AST
(r=0.63, p<0.001), and bilirubin (r=0.64,
p<0.001) concentrations.  Manganese and biliru-
bin concentrations declined after manganese
supplements were reduced or withdrawn.
Results of this study support the association
between cholestasis and hypermanganesemia but
do not provide evidence that the latter causes the
former.  A comparison of two groups of infants
who received either high or low manganese
dosage in parenteral nutrition solutions found no
significant difference in the frequency of
cholestasis.187 Unfortunately, plasma manganese
concentrations were not measured in all infants.
Manganese and bilirubin may have additive
toxic effects on the biliary canalicular
membrane.188, 189 Although an association was
found between elevated whole blood manganese
concentrations and plasma alkaline phosphatase
and GGT concentrations, no conclusion could be
drawn as to whether hypermanganesemia caused
cholestasis.190, 191 It is also unclear whether blood
manganese concentrations reflect liver and tissue
manganese stores.180 Nevertheless, monitoring
manganese concentrations is particularly
important in patients with PNAC, and restriction
of manganese is necessary to avoid its
accumulation.
Nutritional Deficiencies
Taurine Deficiency
Taurine is a sulfur-containing b-amino acid
derived from cysteine.  One of the many
physiologic functions of taurine is in bile acid
conjugation.159 Animal studies suggest that
taurine improves bile flow and protects against
sulfolithocholate- and LCA-induced liver
injury.192, 193 It prevented parenteral nutrition-
associated liver membrane damage and
maintained bile flow in guinea pigs.194
Taurine becomes a conditionally essential
amino acid in premature infants159, 195 who are at
risk for a deficiency due to decreased hepatic
cystathionase activity159 and increased taurine
losses in the kidneys.196 The deficiency may be
aggravated in patients with advanced liver disease
due to decreased liver ability to convert
methionine to cysteine.156 Low plasma taurine
concentrations were reported in children
receiving long-term parenteral nutrition without
taurine supplementation.197–199 Taurine 1.5–2.25
g/day in parenteral nutrition solutions returned
plasma concentrations to normal after 6 weeks.197
Some reports did not support taurine
supplementation’s protective effect on the liver.
Short-term supplementation to parenteral
nutrition of 20 premature infants at 10.8
mg/kg/day for 10 days did not result in a different
effect on hepatic function.200 In children
dependent on home parenteral nutrition who
developed cholestasis, supplementation did not
improve liver function tests despite a significant
increase in blood taurine concentrations.201 In a
retrospective review of the frequency of
cholestasis in infants who received two different
commercial parenteral amino acid formulations
supplemented with taurine (25 and 70 mg/100
ml bulk solution), PNAC occurred in 21.4% of
subjects (15/70 patients) in equal numbers of
those who received either formulation for at least
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14 days.37 This frequency fell within the range
reported for PNAC in infants receiving parenteral
nutrition without taurine supplementation.
However, limitations to this study included its
retrospective nature, small sample, and various
underlying medical and surgical conditions in
subjects that may have affected the results.
In summary, taurine supplementation improves
bile flow and enhances bile acid conjugation.202
Low taurine and high methionine plasma
concentrations in infants with PNAC led
investigators to suggest that taurine deficiency
may impair bile acid conjugation, resulting in
cholestasis.157 Accordingly, the formulation of
some neonatal parenteral amino acids was
changed to include taurine in amounts to
maintain normal plasma concentrations.37, 203, 204
However, no correlation has been found between
low plasma taurine concentrations and
cholestasis, and no strong evidence suggests that
returning plasma taurine concentrations to
normal would prevent PNAC.
Carnitine Deficiency
Carnitine is a quaternary amine synthesized in
the liver and kidneys from lysine and
methionine.  Its primary function is to transport
long-chain fatty acids across the mitochondrial
membrane for oxidation and generation of ATP.205
Carnitine becomes essential in premature infants
who are at risk for deficiency due to their limited
reserves and reduced capacity for carnitine
biosynthesis.206, 207
Based on reports of hepatic steatosis in
carnitine-deficient patients and results of animal
studies, the deficiency may be a factor in the
pathogenesis of parenteral nutrition-associated
liver dysfunction.208, 209 A patient with systemic
carnitine deficiency also had elevated liver
enzyme concentrations, hepatomegaly, and
steatosis.210 In animal studies, carnitine
supplementation reduced liver fat deposition that
was induced with hypercaloric parenteral
nutrition211 and prevented alcohol-induced
hepatic steatosis.212
In children, low serum carnitine concen-
trations213–216 and depletion of tissue stores were
associated with carnitine-free parenteral
nutrition.217 In other human reports, adding
carnitine to parenteral nutrition returned plasma
carnitine concentrations to normal, enhanced
ketogenesis and fat metabolism,218–220 reduced
hepatocyte fatty infiltration,208 and reversed the
hyperbilirubinemia.209 As a result, the
improvement in fat metabolism led to the
suggestion that carnitine supplementation
mobilizes hepatic lipid stores and prevents
steatosis in parenteral nutrition-dependent
patients.  However, supplementation for 1 month
in four adults receiving parenteral nutrition
returned plasma and liver carnitine levels to
normal but did not improve steatosis.221
Carnitine is not routinely added to parenteral
nutrition.  L-Carnitine for intravenous adminis-
tration is stable and compatible with parenteral
nutrition solutions.222, 223 The optimal dosage to
prevent deficiency is not well defined, but 3–10
mg/kg/day added to neonatal parenteral nutrition
is suggested when the duration of parenteral
nutrition administration exceeds 2 weeks.224
Low plasma carnitine concentrations may not
necessarily reflect tissue stores and may have no
correlation with hepatic dysfunction associated
with parenteral nutrition.216 It remains to be
established whether routine carnitine
supplementation in children prevents liver
dysfunction associated with parenteral nutrition.
Nonpharmacologic Management
Enteral Feeding
Enteral feeding reverses the intestinal mucosal
hypoplasia induced by starvation,102 preserves
immunologic integrity of gut-associated lymphatic
tissue,78 prevents bacterial translocation,139 and
protects against PNAC.106 In animal studies,
parenteral nutrition-fed rats had significantly
higher bacterial translocation from the intestines
into mesenteric lymph nodes than enterally fed
rats (p<0.014).  No bacteria were cultured from
the liver, spleen, or blood of rats in either group.
Translocating bacteria were E. coli and Proteus
mirabilis.  The parenteral nutrition-fed rats also
had higher cecal bacterial overgrowth and
decreased intestinal IgA levels than enterally fed
rats.79
Despite accumulated evidence of the protective
effects of enteral feeding, a recent study in
animals raised doubts about the efficacy of
commercial liquid enteral feeding formulas in
preventing bacterial translocation.  Mice fed with
such formulas had a significant increase in
intestinal bacterial overgrowth (p<0.01) and
bacterial translocation to the mesenteric lymph
nodes (p<0.05) compared with chow-fed
controls.225 The clinical significance of these
results and the effect of enteral formulas on
bacterial translocation in humans is unknown.
In humans, PNAC is more common in children
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who do not receive enteral feeding than in those
who do.18, 41 Lower serum levels of interleukins
and endotoxins were found in stressed patients
who received enteral feeding compared with
those who received parenteral nutrition,
suggesting a protective effect of enteral feeding.226
Even small amounts of trophic feeding reduce
intestinal stasis, diminish bacterial translocation,
and improve bile flow.98 Infants who waited for a
mean of 34 days before starting enteral feeding
developed PNAC; however, none of those who
received enteral feeding after a mean fast of 14
days had PNAC.9
Starting enteral feeding early delays the
appearance of liver dysfunction18 and leads to
resolution of jaundice.43 Considering the benefits
of maintaining the functional and structural
integrity of the gut, early enteral feeding, even in
small amounts, is the most established means to
prevent parenteral nutrition-associated liver
dysfunction.
Cyclic Parenteral Nutrition Infusion
Standard administration of parenteral nutrition
for hospitalized patients is by continuous
infusion over 24 hours.  Cyclic parenteral
nutrition refers to infusion over less than 24
hours, usually at night, to provide the patient
with time off the intravenous and pump
apparatus.
Cyclic or intermittent parenteral nutrition
reduces hepatic complications associated with
continuous infusion.  Because continuous
dextrose infusion results in hyperinsulinemia and
fat deposition in the liver,227, 228 cyclic parenteral
nutrition may avoid compulsive overloading of
the liver with dextrose and other nutrients.117,
229–232 Cyclic infusion over 16 hours led to a
decrease in liver enzyme concentrations,
improvement in hepatomegaly, and resolution of
jaundice.232 Serum conjugated bilirubin
concentrations decreased or stabilized after
parenteral nutrition cycling in infants.229 Liver
enzyme concentrations were reduced and
hepatomegaly improved after cycling for 2–3
weeks over 14–16 hours with 8–10 hours of
dextrose-free infusions.230
When patients are expected to receive long-
term parenteral nutrition, early cycling is
recommended, with the usual goal over 10–14
hours.  However, premature infants may
experience fluctuations in blood glucose
concentrations with short cycles.  This is
primarily due to their limited glycogen stores and
immaturity of their glucose-regulatory
mechanisms.233 For instance, hyperglycemia may
occur at high dextrose infusion rates, whereas
rebound hypoglycemia may occur after abrupt
discontinuation of parenteral nutrition.234 To
avoid short-term changes in blood glucose and
insulin concentrations, the parenteral nutrition
cycle usually is advanced over 2 hours and
tapered off over 2 hours.  Blood glucose
concentrations are monitored at peak infusion
rate and 30 minutes after parenteral nutrition is
discontinued.
Pharmacologic Management
Ursodeoxycholic Acid
Ursodeoxycholic acid (urosodiol) is a naturally
occurring hydrophilic bile acid formed in the
liver and intestines.  It plays a role in stimulating
bile production and reducing cholesterol
absorption and hepatic cholesterol synthesis,235
allowing cholesterol gallstone dissolution.89 It is
passively absorbed from the intestines.
Approximately 50–70% of UDCA undergoes first-
pass hepatic metabolism.89, 236 In the liver, it is
conjugated with glycine and taurine and secreted
in bile.  The pharmacology of UDCA is reviewed
elsewhere.89
The exact mechanisms by which UDCA exerts
its protective effects on the liver are unknown.  It
is proposed that UDCA protects the liver by
improving bile flow, displacing toxic bile acids,
exerting immunoprotective effects on hepato-
cytes,237 and protecting against endotoxemia by
reducing intestinal endotoxin translocation238
and enhancing endotoxin biliary excretion.239
Since UDCA is a minor bile acid in humans, it
is suggested that low bile concentrations allow
retention of toxic bile acids.  Accumulation of
toxic bile acids may lead to precipitation of
cholesterol and calcium bilirubinate in form of
gallstones or may even lead to cholestasis.
Therefore, exogenous administration would
enrich the bile with UDCA to displace toxic bile
acids.85, 240
In addition to its benefits in improving
PNAC,92–94, 241, 242 UDCA relieves pruritus.243 In
children with intrahepatic cholestasis, dosages of
15–20 mg/kg/day improved pruritus and reduced
serum ALT and GGT concentrations.94 In
children with PNAC, serum bilirubin
concentrations decreased after 2 weeks of
treatment with UDCA 15–30 mg/kg/day.92
Similarly, UDCA 30 mg/kg/day resulted in
resolution of hepatomegaly and jaundice within
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1–2 weeks and normal liver enzyme concen-
trations within 4–8 weeks in children with
PNAC.93 A rebound increase in liver enzyme
concentrations occurred after discontinuation of
UDCA.93, 94, 241 In adults with PNAC, UDCA
improved serum GGT, ALT,241 and bilirubin
concentrations.242 However, results in adults may
not be extrapolated to children since the
pathophysiologic changes of parenteral nutrition-
associated liver dysfunction differ in the two
populations.244
The agent is available as the protonated acid in
capsule forms for oral administration.  Although
intestinal absorption may be slow and
incomplete, in patients with chronic liver
dysfunction, UDCA 8–12 mg/kg/day increases
biliary concentrations by 30–60%.89 The
problem with absorption remains in patients with
short bowel syndrome, in whom absorption is
unreliable due to significant intestinal resection,
chronic diarrhea, and gastric acid hyper-
secretion.85, 109 In such patients, an extempora-
neously prepared UDCA solution would be better
absorbed than the capsule form.85 Since UDCA is
a weak acid, its solubility increases at alkaline
intestinal pH above  8 unless it is solubilized with
micelles.  This alkaline pH is achieved only after
meals, assuming sustained pancreatic secretions.
An enteric-coated capsule in a pH-sensitive
polymer was formulated to bypass poor intestinal
absorption of protonated form, although it is not
available in the U.S.  It releases UDCA in the
small intestines at pH 5.5 or greater, making it
better absorbed than the regular capsule.245
Although UDCA is not approved for pediatric
use,246 it has been given in dosages of 10–20
mg/kg/day in children with cholestasis.247 Up to
30 mg/kg/day divided in three doses was given to
children with PNAC.92, 93, 248 Gastrointestinal side
effects include diarrhea, nausea, and abdominal
pain.241, 248 Although UDCA may improve clinical
signs and symptoms of cholestasis, it does not
alter disease progression.  Thus, the effects of
prolonged therapy on the course and prognosis
of cholestasis are unknown.94 Prospective,
controlled studies are necessary to assess the
agent’s effects on morbidity and mortality in
children with PNAC.
Cholecystokinin-Octapeptide
Cholecystokinin-octapeptide (CCK-OP,
Sincalide) is the synthetic C-terminal octapeptide
fragment of CCK that produces the biologic
activities of CCK.  In a preliminary human study,
prophylactic CCK-OP prevented biliary sludge in
adults receiving long-term parenteral nutrition.249
Eight infants with PNAC had improvements in
serum conjugated bilirubin concentrations and
resolution of jaundice after intravenous
administration of lyophilized porcine CCK.
Although the authors advocated that CCK may
reverse PNAC, seven patients were weaned from
parenteral nutrition before CCK administration,
one patient did not respond to repeated CCK,
and a control group was absent.100 In a pilot
study of 11 infants with PNAC, CCK-OP caused
reductions in serum conjugated bilirubin
concentrations without significant effects on AST,
ALT, and alkaline phosphatase levels.101
However, five patients were receiving enteral
feeding and two no longer were receiving
parenteral nutrition.  Enteral feeding and
parenteral nutrition cessation may have led to the
reduction in bilirubin.  Also, a statistically
significant decrease in hyperbilirubinemia was
achieved only after three patients with liver
failure were excluded.  If these three patients had
PNAC, this raises the question of whether CCK-
OP has a role in advanced liver disease.
In a subsequent study, CCK-OP was administered
to 21 neonates with PNAC who had received
parenteral nutrition over 14 days.250 The starting
dosage was 0.02 µg/kg twice/day and increased to
0.04 µg/kg 3 times/day if parenteral nutrition was
continued over 14 days.  The control group
consisted of infants with PNAC who were
matched with the experimental group.  Although
CCK-OP slightly lowered serum conjugated
bilirubin concentrations, the frequency of PNAC
at concentrations greater than 2 mg/dl was not
statistically significant between groups.  Patients
were allowed enteral feeding, which could have
improved cholestasis independently.
Although in early animal studies CCK-OP
prevented bile stasis associated with parenteral
nutrition,251, 252 the same benefits were not
reproduced in later studies.253, 254 The agent did
not improve bile flow or bile acid secretion
despite slight improvements in liver fibrosis and
portal inflammation.253 Also, it did not prevent
gallstone formation and did not return the bile
salt profile to normal despite improvements in
bile acid synthesis and output.254
Currently, CCK-OP is not approved for
prevention or treatment of cholestasis.  It is
available in injectable forms for intravenous and
intramuscular administration.  At dosages used
in studies, it appears safe but with a commonly
reported side effect of abdominal cramping100, 101,
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249 that is likely dose related.250 From study
reports, CCK-OP appears to improve the clinical
signs of cholestasis, but its long-term effects in
preventing PNAC are unknown.
Enteral Antibiotics
Bacterial overgrowth is a common compli-
cation in children with short bowel syndrome.255
Treatment is crucial to reduce intestinal bacterial
overload and minimize bacterial and endotoxin
toxic effects on the liver.  Improvements in liver
enzyme concentrations after treatment with
antibiotics that target intestinal bacteria suggest a
role of these bacteria in the pathogenesis of
parenteral nutrition-associated liver dysfunction.
Although different antibiotics are administered to
treat bacterial overgrowth in patients with PNAC,
no clear consensus on the choice of drug exists.
Metronidazole256–260 and oral nonabsorbable
antibiotics such as gentamicin,261 kanamycin,68
neomycin,79 and polymyxin B65, 71 are effective.
Metronidazole
The ability of metronidazole to prevent liver
injury in rats suggests a role of anaerobic
bacteria, particularly Bacteroides sp, in the
pathogenesis of hepatic injury associated with
bacterial overgrowth.256, 258, 260 In animals,
reduction of intestinal anaerobic flora by the
agent was associated with a reduction in hepatic
lipid content.259 In humans, the drug prevented
steatosis in obese patients with jejunoileal
bypass.262 This effect possibly was mediated
through inhibition of jejunal bacterial
overgrowth and intestinal deconjugation of bile
acids, a known complication of jejunoileal bypass
surgery.263 In a retrospective review of adults
who received parenteral nutrition, metronidazole
given intravenously, orally, or rectally prevented
elevations of serum alkaline phosphatase, GGT,
and AST concentrations.258 Reductions in liver
enzyme concentrations were similarly reported
after oral256 or intravenous264 administration to
adults with parenteral nutrition-associated liver
dysfunction.
Metronidazole does not improve liver enzyme
concentrations in advanced liver disease.114
Intravenous administration in infants receiving
parenteral nutrition did not have a significant
effect on the frequency of hyperbilirubinemia.
Only infants who received metronidazole 50
mg/kg/day had significantly lower serum AST
and ALT concentrations compared with infants in
the control group (p<0.05).257
Gentamicin
Very low-birthweight infants who were given
oral gentamicin for prophylaxis of necrotizing
enterocolitis while receiving parenteral nutrition
had less significant increases in serum conjugated
bilirubin concentrations than infants with
significantly higher serum bilirubin
concentrations who did not receive the drug.
The frequency of cholestasis was 8% and 42%,
respectively.  Also, patients receiving gentamicin
had no significant rise in serum conjugated
bilirubin concentrations from baseline after
starting parenteral nutrition.261
Neomycin
Oral neomycin given to rats reduced the
frequency of bacterial translocation and the
number of cecal gram-negative bacteria.79 The
drug protected against fibrosis, cirrhosis, and
fatty infiltration of the liver.  Since oral
administration of endotoxins reversed these
protective effects, it was concluded that
neomycin protects against liver injury by
suppressing intraluminal bacterial growth.265
Polymyxin B
Oral polymyxin B decreased cecal flora, TNF
production, and hepatic steatosis in rats given
parenteral nutrition.65, 71 In vitro experiments
showed polymyxin B binds and inactivates the
lipid A-core region of the lipopolysaccharide
portion of endotoxins.266 Besides its bactericidal
effect on enteral gram-negative bacteria, the
agent may prevent release of TNF by
macrophages in response to lipopolysaccharides
and protect against lipopolysaccharide-induced
liver toxicity and steatosis.65, 71
Enzyme Inducers
Phenobarbital
Phenobarbital may improve cholestasis
possibly by enhancing conjugation of
bilirubin.267, 268 Results of the effects of
phenobarbital in cholestasis are inconsistent.  In
a premature infant with PNAC, 5 mg/kg/day
improved hyperbilirubinemia that did not
respond to discontinuation of parenteral
nutrition; hyperbilirubinemia recurred after
phenobarbital was discontinued.266 However, in
two other case reports, the same dosage did not
improve hyperbilirubinemia in infants with
PNAC.140 In a retrospective review of medical
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records of 31 infants who were treated with
phenobarbital for neurologic conditions while
receiving parenteral nutrition, 60% developed
cholestasis, compared with 33% of untreated
infants.268
Based on published reports, the role
phenobarbital in relieving PNAC is uncertain.  In
addition, there is concern about worsening
intrahepatic cholestasis with the agent in
children with obstructive cholangiopathy.269
Rifampin
Rifampin may be more effective than
phenobarbital in relieving pruritus in patients
with primary biliary cirrhosis.270 A dosage of 10
mg/kg/day was effective in relieving pruritus271
and improving GGT levels in children with
cholestasis who failed UDCA, phenobarbital, or
antihistamine therapy.272 Improvements in
cholestasis and pruritus also were reported with
the drug in adults with primary biliary
cirrhosis.270, 273 Although the exact mechanism of
action of rifampin in relieving pruritus is
unknown, proposed mechanisms include
enhancing metabolism of bile acids or
pruritogenic substances,273 diminishing the pool
of toxic bile acids,270 and inhibiting bile acid
uptake by hepatocytes.274 Due to the drug’s
potentially serious side effects, such as toxic
hepatitis,273 hemolytic anemia, and renal
failure,270 other safer agents such as
cholestyramine or UDCA should be considered
first for treating the pruritus of cholestasis.243, 275
Cholestyramine
Cholestyramine is an insoluble ion exchange
resin that forms a nonabsorbable complex with
bile acids in the intestines.  It relieves pruritus
associated with intrahepatic cholestasis276 and
alleviates diarrhea after ileal resection.277
Cholestyramine also binds the endotoxins in the
intestines and may prevent their translocation.278
However, this effect may be clinically insignifi-
cant because it is partial and short lived.279
The agent’s role in treating bile acid-induced
diarrhea in patients with ileal resection is
explained by its binding capacity of excess bile
acids in the colon to prevent salt and water
secretion.280, 281 Its ability to relieve pruritus of
cholestasis is probably due to its effect on
lowering levels of bile acids and other
pruritogenic mediators.275, 282
The usual dosage of cholestyramine in children
is 240 mg/kg/day divided in three doses.283
Constipation, diarrhea, nausea, and abdominal
discomfort are reported adverse effects.276 Due to
its drug-binding capacity, cholestyramine may
bind UDCA when the two are given concurrently
to patients with cholestasis.284 To avoid clinically
significant drug-drug interactions, other oral
agents should be given 1 hour before and 4–6
hours after cholestyramine administration.285
Intestine Transplantation
Despite improvements in transplantation
outcomes over the past 10 years, long-term
results of liver and small bowel transplantation as
alternatives to parenteral nutrition in patients
with refractory short bowel syndrome are
unknown.286 The choice of isolated small bowel
versus combined small bowel-liver transplan-
tation depends on the extent of liver disease.
The 1-year worldwide survival rate after 1995
was 69% for intestinal transplants and 66% for
small bowel-liver transplants.119 Worldwide 5-
year survival was 50% for small bowel
transplants and 40% for combined small bowel-
liver transplants.287
Intestine transplantation resulted in stopping
parenteral nutrition in 77% of survivors119 who
later were able to achieve normal growth and
weight gain with oral feeding.120, 287 When
considering the procedure in parenteral
nutrition-dependent patients, complications
(rejection, infection, lymphoproliferative
disease)119, 287 and quality of life should be taken
into consideration.288 Until a higher survival rate
is achieved, and given the high survival rate in
patients receiving home parenteral nutrition,289
intestine transplantation seems warranted only
when all therapies fail and when the patient has
life-threatening complications.115, 119, 120 In
addition, patients may benefit from other types of
organ transplantations, such as isolated
orthotopic liver transplantation, that might be an
alternative in infants with end-stage liver disease.
To be considered for that procedure, patients
should have significant tolerance to enteral
feeding and have sufficient small bowel with a
good probability of eventual gut adaptation.290
As experience grows, it may become possible to
perform bowel transplantation early before
hepatic failure develops, especially if more
selective and powerful immunosuppressive
therapies become available.
Summary
Several interventions can be undertaken to
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prevent parenteral nutrition-associated
hepatobiliary dysfunction (Table 1).  The
disorder is reversible when parenteral nutrition is
discontinued and enteral feeding is begun early
before irreversible liver damage has occurred.
Recommended methods to prevent liver
dysfunction include limiting the duration of
parenteral nutrition, starting enteral feeding early,
avoiding overfeeding, vigilant prevention and
prompt treatment of sepsis, and cyclic parenteral
nutrition.  Prophylactic administration of UDCA
is likely beneficial, but its role in treatment of
PNAC requires further studies.  Therapy with
CCK-OP to prevent and treat PNAC yields
inconsistent results, and its effects in advanced
liver disease are questionable.  Bowel
decontamination with enteral antibiotics may be
beneficial when clinical conditions predispose to
bacterial overgrowth.  It is essential to monitor
liver enzyme concentrations regularly during
parenteral nutrition to allow early detection of
liver abnormalities.  Liver biopsies may be
necessary when the diagnosis is uncertain.
Patients with short bowel syndrome and severe
liver dysfunction should be assessed for
combined bowel and liver transplantation.
References
1. Rodgers BM, Hollenbeck JI, Donnelly WH, Talbert JL.
Intrahepatic cholestasis with parenteral alimentation. Am J
Surg 1976;131:149–55.
2. Postuma R, Trevenen CL. Liver disease in infants receiving
total parenteral nutrition. Pediatrics 1979;63:110–15.
3. Quigley EMM, Marsh MN, Shaffer JL, Markin RS .
Hepatobiliary complications of total parenteral nutrition.
Gastroenterology 1993;104:286–301.
4. Kelly DA. Liver complications of pediatric parenteral
nutrition—epidemiology. Nutrition 1998;14:153–7.
5. Payne-James JJ, Silk DBA. Hepatobiliary dysfunction
associated with total parenteral nutrition. Dig Dis
1991;9:106–24.
6. Sandhu IS, Jarvis C, Everson GT. Total parenteral nutrition
and cholestasis. Clin Liver Dis 1999;3:489–508.
7. Suita S, Ikeda K, Nagasaki A, et al. Follow-up studies of
children treated with a long-term intravenous nutrition (IVN)
during the neonatal period. J Pediatr Surg 1982;17:37–42.
8. Suita S, Masumoto K, Yamanouchi T, Nagano M, Nakamoura
M. Complications in neonates with short bowel syndrome and
long-term parenteral nutrition. J Parenteral Enteral Nutr
1999;23:S106–9.
9. Drongowski RA, Coran AG .  An analysis of factors
contributing to the development of total parenteral nutrition-
induced cholestasis. J Parenteral Enteral Nutr 1989;13:586–9.
10. Touloukian RJ, Seashore JH. Hepatic secretory obstruction
with total parenteral nutrition in the infant. J Pediatr Surg
1975;10:353–60.
11. Beale E, Nelson R, Bucciarelli R, Donnelly WH, Eitzman
DV. Intrahepatic cholestasis associated with parenteral
nutrition in premature infants. Pediatrics 1979;64:342–7.
12. Nanji AA, Anderson FH. Sensitivity and specificity of liver
function tests in the detection of parenteral nutrition-
associated cholestasis. J Parenteral Enteral Nutr
1985;9:307–8.
13. Beath SV, Booth IW, Murphy MS, et al. Nutritional care and
candidates for small bowel transplantation. Arch Dis Child
1995;73:348–50.
14. Hodes JE, Grosfeld JL, Weber TR, Schreiner RL, Fitzgerald
JF, Mirkin LD. Hepatic failure in infants on total parenteral
nutrition (TPN): clinical and histopathologic observations. J
Pediatr Surg 1982;17:463–8.
15. Chan S, McCowen KC, Bistrian BR, et al. Incidence,
prognosis, and etiology of end-stage liver disease in patients
receiving home total parenteral nutrition. Surgery
1999;126:28–34.
16. Ginn-Pease ME, Pantalos D, King DR. TPN-associated
hyperbilirubinemia: a common problem in newborn surgical
patients. J Pediatr Surg 1985;20:436–9.
17. Beath SV, Needham SJ, Kelly DA, et al. Clinical features and
prognosis of children assessed for isolated small bowel or
combined small bowel and liver transplantation. J Pediatr
Surg 1997;32:459–61.
18. Benjamin DR. Hepatobiliary dysfunction in infants and
children associated with long-term total parenteral nutrition.
A clinico-pathologic study. Am J Clin Pathol 1981;76:276–83.
19. Freund HR. Abnormalities of liver function and hepatic
damage associated with total parenteral nutrition. Nutrition
204
Table 1.  Measures to Prevent Parenteral Nutrition-Associated Hepatobiliary Dysfunction
Measure Rationale
Avoid overfeeding Avoid compulsive liver overload with nutrients
Avoid excessive dosages of any micronutrient Avoid excessive liver overload with macronutrients (amino acids, dextrose,
lipids), prevent deficiencies
Start enteral feeding early Preserve intestinal integrity, maintain intestinal hormone and enzyme
secretion, prevent bacterial translocation
Cycle parenteral nutrition Avoid continuous liver overload with nutrients
Avoid sepsis, aggressively treat sepsis Avoid bacterial and endotoxin hepatotoxic effects on hepatocytes and bile
flow
Administer ursodiol Enhance bile flow, reduce hepatotoxic bile acids
Administer cholecystokinin Improve gallbladder contractility, stimulate bile
Administer enteral antibiotics Inhibit bacterial overgrowth
Administer cholestyramine Treat pruritus associated with cholestasis, reduce diarrhea with short bowel
syndrome
PARENTERAL NUTRITION AND LIVER COMPLICATIONS IN CHILDREN  Btaiche and Khalidi
1991;7:1–6.
20. Sheldon GF, Peterson SR, Sanders R. Hepatic dysfunction
during hyperalimentation. Arch Surg 1978;113:504–8.
21. Vileisis RA, Inwood RJ, Hunt CE. Laboratory monitoring of
parenteral nutrition-associated hepatic dysfunction in infants.
J Parenteral Enteral Nutr 1981;5:67–9.
22. Dahms BB, Halpin TC. Serial liver biopsies in parenteral
nutrition-associated cholestasis of early infancy.
Gastroenterology 1981;81:136–44.
23. Manginello FP, Javitt NB. Parenteral nutrition and neonatal
cholestasis. J Pediatr 1979;94:296–8.
24. Farrell MK, Balistreri WF, Suchy FJ . Serum-sulfated
lithocholate as an indicator of cholestasis during parenteral
nutrition in infants and children. J Parenteral Enteral Nutr
1982;6:30–3.
25. Demircan M, Ergun O, Avanoglu S, Yilmaz F, Ozok G.
Determination of serum bile acids routinely may prevent
delay in diagnosis of total parenteral nutrition-associated
cholestasis. J Pediatr Surg 1999;34:565–7.
26. Balistreri WF, Suchy FJ, Farrell MK, Heubi JE. Pathologic
versus physiologic cholestasis: elevated serum concentration
of a secondary bile acid in the presence of hepatobiliary
disease. J Pediatr 1981;98:399–402.
27. Black DD, Whitington PF, Korones SD. The effect of short-
term total parenteral nutrition on hepatic function in the
human neonate: a prospective randomized study
demonstrating alteration of hepatic canalicular function. J
Pediatr 1981;99:445–9.
28. Sondheimer JM, Bryan H, Andrews W, Forstner GG.
Cholestatic tendencies in premature infants on and off
parenteral nutrition. Pediatrics 1978;62:984–9.
29. Beckett GJ, Glass EJ, Callaghan MO, Elton RA, Hume RA.
Measuring bile-salt concentrations lacks clinical value for
detecting hepatic dysfunction in infants receiving parenteral
nutrition. Clin Chem 1985;31:1168–71.
30. Rosalki SB. Gamma-glutamyl transpeptidase. Adv Clin Chem
1975;17:53–107.
31. Penn R, Worthington DJ. Is serum gamma-glutamyl-
transferase a misleading test?  Br Med J 1983;286:531–5.
32. Goldberg DM, Martin JF .  Role of gamma-glutamyl
transpeptidase activity in the diagnosis of hepatobiliary
disease. Digestion 1975;12:232–46.
33. Nanji AA, Filipenko JD. Unusual alkaline phosphatase
isoenzyme pattern associated with parenteral nutrition
[letter]. J Parenteral Enteral Nutr 1984;8:53.
34. Lucas A, Brooke OG, Baker BA, Bishop N, Morley R. High
alkaline phosphatase activity and growth in preterm neonates.
Arch Dis Child 1989;64:902–9.
35. Zarif MA, Pildes RS, Szanto PB, Vidyasagar D. Cholestasis
associated with administration of L-amino acids and dextrose
solutions. Biol Neonate 1976;29:66–76.
36. Bell RL, Ferry GD, Smith EO, et al. Total parenteral
nutrition-related cholestasis in infants. J Parenteral Enteral
Nutr 1986;10:356–9.
37. Forchielli ML, Gura KM, Sandler R, Lo C. Aminosyn PF or
trophamine: which provides more protection from cholestasis
associated with total parenteral nutrition? J Pediatr
Gastroenterol Nutr 1995;21:374–82.
38. Teitelbaum DH, Drongowski R, Spivak D .  Rapid
development of hyperbilirubinemia in infants with the short
bowel syndrome as a correlate to mortality: possible
indication for early small bowel transplantation. Transplant
Proc 1996;28:2699–700.
39. Beath S, Davies P, Papadpoulou A, et al. Parenteral nutrition-
related cholestasis in postsurgical neonates: multivariate
analysis of risk factors. J Pediatr Surg 1996;31:604–6.
40. Pereira GR, Sherman MS, DiGiacomo J, Ziegler M, Roth K,
Jacobowski D. Hyperalimentation-induced cholestasis:
increased frequency and severity in premature infants. Am J
Dis Child 1981;135:842–5.
41. Colomb V, Goulet O, Rambaud C, et al. Long-term parenteral
nutrition in children: liver and gallbladder disease. Transplant
Proc 1992;24:1054–5.
42. Cavicchi M, Beau P, Crenn P, Degott C, Messing B .
Prevalence of liver disease and contributing factors in patients
receiving home parenteral nutrition for permanent intestinal
failure. Ann Intern Med 2000;132:525–32.
43. Barbier J, Gineste D, Kraimps JL, et al. Hepatobiliary
complications of total parenteral nutrition. Chirurgie
1992;118:47–54.
44. Ito Y, Shils ME. Liver dysfunction associated with long-term
total parenteral nutrition in patients with massive bowel
resection. J Parenteral Enteral Nutr 1991;15:271–6.
45. Balistreri WF. Immaturity of hepatic excretory function and
the ontogeny of bile acid metabolism. J Pediatr Gastroenterol
Nutr 1983;2(suppl 1):S207–14.
46. Balistreri WF, Heubi JE, Suchy FJ. Immaturity of the
enterohepatic circulation in early life: factors predisposing to
“physiologic” maldigestion and cholestasis. J Pediatr
Gastroenterol Nutr 1983;2:346–54.
47. Rannem T, Ladefoged K, Tvede M, Lorentzen JE, Jarnum S.
Catheter-related septicaemia in patients receiving home
parenteral nutrition. Scand J Gastroenterol 1986;21:455–60.
48. Pierro A, van Saene HKF, Donnell SC, et al. Microbial
translocation in neonates and infants receiving long-term
parenteral nutrition. Arch Surg 1996;131:176–9.
49. Page S, Abel G, Stringer MD, Puntis JWL. Management of
septicaemia during long-term parenteral nutrition. Int J Clin
Pract 2000;54:147–50.
50. Beau P, Barrioz T, Ingrand P. Total parenteral nutrition-
related cholestatic hepatopathy, is it an infectious disease?
Gastroenterol Clin Biol 1994;18:63–7.
51. Franson TR, Hierholzer WJ, LaBrecque DR. Frequency and
characteristics of hyperbilirubinemia associated with
bacteremia. Rev Infect Dis 1985;7:1–9.
52. Rooney JC, Hill DJ, Danks DM. Jaundice associated with
bacterial infection in the newborn. Am J Dis Child
1971;122:39–41.
53. Seeler RA, Hahn K. Jaundice in urinary tract infection in
infancy. Am J Dis Child 1969;118:553–8.
54. Ng SH, Rawstron JR. Urinary tract infections presenting with
jaundice. Arch Dis Child 1971;46:173–6.
55. Hamilton JR, Sass-Kortsak A. Jaundice associated with severe
bacterial infection in young infants. J Pediatr 1963;63:121–32.
56. Buchmiller CE, Kleiman-Wexler RL, Ephgrave KS, Booth B,
Hensley CE. Liver dysfunction and energy source: results of a
randomized clinical trial. J Parenteral Enteral Nutr
1993;17:301–6.
57. Clark PJ, Bail MJ, Kettlewell MG. Liver associated tests in
patients receiving parenteral nutrition. J Parenteral Enteral
Nutr 1991;15:54–9.
58. Bernstein J, Brown AK. Sepsis and jaundice in early infancy.
Pediatrics 1962;29:873–82.
59. Gonnella PA, Helton WS, Robinson M, Wilmore DW. O-side
chain of Escherichia coli endotoxin 0111:B4 is transported
across the intestinal epithelium in the rat: evidence of
increased transport during total parenteral nutrition. Eur J
Cell Biol 1992;59:224–7.
60. Nolan JP .  The role of endotoxin in liver injury.
Gastroenterology 1975;69:1346–56.
61. Utili R, Abernathy CO, Zimmerman HJ. Cholestatic effects of
Escherichia coli endotoxin on the isolated perfused rat liver.
Gastroenterology 1976;70:248–53.
62. Utili R, Abernathy CO, Zimmerman HJ. Inhibition of Na+,
K+-adenosinetriphosphate by endotoxin: a possible
mechanism for endotoxin-induced cholestasis. J Infect Dis
1977;136:583–7.
63. Fouin-Fortunet H, Le Quernec L, Erlinger S, Lerebours E,
Colin R. Hepatic alterations during total parenteral nutrition
in patients with inflammatory bowel disease: a possible
consequence of lithocholate toxicity. Gastroenterology
1982;82:932–7.
64. Sakisaka S, Koga H, Sasatomi K, Mimura Y, Kawaguchi T,
Tanikawa K. Biliary secretion of endotoxin and pathogenesis
of primary biliary cirrhosis. Yale J Biol Med 1997;70:403–8.
65. Pappo I, Becovier H, Berry EM, Freund HR. Polymyxin B
205
PHARMACOTHERAPY  Volume 22, Number 2, 2002
reduces cecal flora, TNF production and hepatic steatosis
during total parenteral nutrition in the rat. J Surg Res
1991;51:106–12.
66. Vromen A, Spira RM, Bercovier H, Berry E, Freund HR.
Pentoxifylline and thalidomide fail to reduce hepatic steatosis
during total parenteral nutrition and bowel rest in the rat. J
Parenteral Enteral Nutr 1997;21:233–4.
67. Utili R, Abernathy CO, Zimmerman HJ. Endotoxin effects on
the liver. Life Sci 1977;20:553–68.
68. Latham PS, Menkes E, Phillips MJ, Jeejeebhoy KN .
Hyperalimentation-associated jaundice: an example of a
serum factor inducing cholestasis in rats. Am J Clin Nutr
1985;41:61–5.
69. Campbell LV, Gilbert EF .  Experimental giant-cell
transformation in the liver induced by E-coli endotoxin. Am J
Pathol 1967;51:855–68.
70. Pappo I, Bercovier H, Berry E, Gallilly R, Feigin E, Freund
HR. Antitumor necrosis factor antibodies reduce hepatic
steatosis during total parenteral nutrition and bowel rest in
the rat. J Parenteral Enteral Nutr 1995;19:80–2.
71. Pappo I, Bercovier H, Berry EM, Haviv Y, Gallily R, Freund
HR. Polymyxin B reduces total parenteral nutrition-associated
hepatic steatosis by its antibacterial activity and by blocking
deleterious effects of lipopolysaccharide. J Parenteral Enteral
Nutr 1992;16:529–32.
72. Feingold KR, Serio MK, Adi S, Moser AH, Grunfeld C.
Tumor necrosis factor stimulates hepatic lipid synthesis and
secretion. Endocrinology 1989;124:2336–42.
73. Jones A, Selby PJ, Viner C, Hobbs S, Gore ME, McElwain TJ.
Tumor necrosis factor, cholestatic jaundice, and chronic liver
disease. Gut 1990;31:938–9.
74. O’Dwyer ST, Michie HR, Ziegler TR, Revhaug A, Smith RJ,
Wilmore DW. A single dose of endotoxin increases intestinal
permeability in healthy humans. Arch Surg
1988;123:1459–64.
75. Deitch EA, Winterton J, Li M, Berg R. The gut as a portal of
entry for bacteremia. Role of protein malnutrition. Ann Surg
1987;205:681–92.
76. Fong Y, Marano MA, Barber A, et al. Total parenteral
nutrition and bowel rest modify the metabolic response to
endotoxin in humans. Ann Surg 1989;210:449–57.
77. Go LL, Healy PJ, Watkins SC, Simmons RL, Rowe MI. The
effect of endotoxin on intestinal mucosal permeability to
bacteria in vitro. Arch Surg 1995;130:53–8.
78. Li J, Kudsk KA, Gocinski B, Dent D, Glezer J, Langkamp-
Henken B. Effects of parenteral and enteral nutrition on gut-
associated lymphoid tissue. J Trauma 1995;39:44–51.
79. Alverdy JC, Aoys E, Moss GS. Total parenteral nutrition
promotes bacterial translocation from the gut. Surgery
1988;104:185–90.
80. Barber AE, Jones WG, Minei JP, Fahey TJ, Lowry SF, Shires
T. Bacterial overgrowth and intestinal atrophy in the etiology
of gut barrier failure in the rat. Am J Surg 1991;161:300–4.
81. Yeung CY, Lee HC, Huang FY, Wang CS. Sepsis during total
parenteral nutrition: exploration of risk factors and
determination of the effectiveness of peripherally inserted
central venous catheters. Pediatr Infect Dis J 1998;17:135–42.
82. Bos AP, Tibboel D, Hazebroek FW, Bergmeijer JH, van
Kalsbeek EJ, Molenaar JC. Total parenteral nutrition
associated cholestasis: a predisposing factor for sepsis in
surgical neonates?  Eur J Pediatr 1990;149:351–3.
83. Jacquemin E, Maurage C, Borderon JC, Gold F, Laugier R,
Rolland JC. Early cholestasis in premature infants receiving
total parenteral nutrition: a possible consequence of shock
and hypoxia. Eur J Pediatr Surg 1995;5:259–61.
84. Roughneen PT, Gouma DJ, Kulkarni AD, Fanslow WF,
Rowlands BJ. Impaired specific cell-mediated immunity in
experimental biliary obstruction and its reversibility by
internal biliary drainage. J Surg Res 1986;41:113–25.
85. Hofmann AF. Defective biliary secretion during total
parenteral nutrition: probable mechanisms and possible
solutions. J Pediatr Gastroenterol Nutr 1995;20:376–90.
86. Rager R, Finegold MJ. Cholestasis in immature newborn
infants: is parenteral alimentation responsible? J Pediatr
1975;86:264–9.
87. Cooper A, Ross AJ, O’Neill JA, Bishop HC, Templeton JM,
Ziegler MM. Resolution of intractable cholestasis associated
with total parenteral nutrition following biliary irrigation. J
Pediatr Surg 1985;20:772–4.
88. Rintala R, Lindahl H, Pohjavuori M, Saxen H, Sariola H.
Surgical treatment of intractable cholestasis associated with
total parenteral nutrition in premature infants. J Pediatr Surg
1993;28:716–19.
89. Hofmann AF. Pharmacology of ursodeoxycholic acid, an
enterohepatic drug. Scand J Gastroenterol 1994;29(suppl
204):1–15.
90. Palmer RH, Ruban Z. Production of bile duct hyperplasia and
gallstones by lithocholic acid J Clin Invest 1966;45:1255–67.
91. Van Nieuwkerk CMJ, Oude Elferink RPJ, Groen EK, et al.
Effects of ursodeoxycholate and cholate feeding on liver
disease in FVB mice with a disrupted mdr2 P–glycoprotein
gene. Gastroenterology 1996;111:165–71.
92. Levine A, Maayan A, Shamir R, Dinari G, Sulkes J, Sirotta L.
Parenteral nutrition-associated cholestasis in preterm
neonates: evaluation of ursodeoxycholic acid treatment. J
Pediatr Endocrinol Metab 1999;12:549–53.
93. Spagnuolo MI, Iorio R, Vegnente A, Guarino A .
Ursodeoxycholic acid for the treatment of cholestasis in
children on long-term total parenteral nutrition: a pilot study.
Gastroenterology 1996;111:716–19.
94. Narkewicz MR, Smith D, Gregory C, Lear JL, Osberg I,
Sokol RJ. Effect of ursodeoxycholic acid therapy on hepatic
function in children with intrahepatic cholestatic liver
disease. J Pediatr Gastroenterol Nutr 1998;26:49–55.
95. Aynsley-Green A. Plasma hormone concentrations during
enteral and parenteral nutrition in the human newborn. J
Pediatr Gastroenterol Nutr 1983;2(suppl 1):S108–12.
96. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA.
Cholecystokinin bioactivity in human plasma. Molecular
forms, responses to feeding, and relationship to gallbladder
contraction. J Clin Invest 1985;75:1144–52.
97. Wang X, Soltesz V, Axelson J, Anderson R. Cholecystokinin
increases small intestine motility and reduces enteral bacterial
overgrowth and translocation in rats with surgically induced
acute liver failure. Digestion 1996;57:67–72.
98. Lucas A, Bloom R, Aynsley-Green A .  Metabolic and
endocrine consequences of depriving preterm infants of
enteral nutrition. Acta Pediatr Scand 1983;72:245–9.
99. Jawaheer G, Pierro A, Lloyd DA, Shaw NJ. Gall bladder
contractility in neonates: effects of parenteral and enteral
feeding. Arch Dis Child 1995;72:F200–2.
100. Rintala RJ, Lindahl H, Pohjavuori M. Total parenteral
nutrition-associated cholestasis in surgical neonates may be
reversed by intravenous cholecystokinin: a preliminary report.
J Pediatr Surg 1995;30:827–30.
101. Teitelbaum DH, Han-Markey T, Schumacher RE. Treatment
of parenteral nutrition associated cholestasis with
cholecystokinin-octapeptide. J Pediatr Surg 1995;30:1082–5.
102. Williamson RCN, Chir M. Intestinal adaptation. Structural,
functional and cytokinetic changes. N Engl J Med
1978;298:1393–1402.
103. Davies GR, Wilkie ME, Rampton DS .  Effects of
metronidazole and misoprostol on indomethacin-induced
changes in intestinal permeability. Dig Dis Sci 1993;38:
417–25.
104. Alverdy J, Chi HS, Sheldon GF. The effect of parenteral
nutrition on gastrointestinal immunity. The importance of
enteral stimulation. Ann Surg 1985;202:681–4.
105. Braxton CC, Coyle SM, Montegut WJ, et al. Parenteral
nutrition alters monocyte TNF receptor activity. J Surg Res
1995;59:23–8.
106. Wilmore DW, Smith RJ, O’Dwyer ST, Jacobs DO, Ziegler TR,
Wang XD. The gut: a central organ after surgical stress.
Surgery 1988;104:917–23.
107. Freund HR. Continuous translocation of endotoxin and
tumor necrosis factor translocation from the unused gut
206
PARENTERAL NUTRITION AND LIVER COMPLICATIONS IN CHILDREN  Btaiche and Khalidi
[letter]. Nutrition 1998;14:399.
108. Kaufman SS, Loseke CA, Lupo JV, et al. Influence of bacterial
overgrowth and intestinal inflammation on duration of
parenteral nutrition in children with short bowel syndrome. J
Pediatr 1997;131:356–61.
109. Booth IW, Lander AD. Short bowel syndrome. Baillieres Clin
Gastroenterol 1998;12:739–73.
110. Cooper A, Floyd TF, Ross AJ, Bishop HC, Templeton JM,
Ziegler MM. Morbidity and mortality of short-bowel
syndrome acquired in infancy: an update. J Pediatr Surg
1984;19:711–18.
111. Iacono G, Carroccio A, Montalto G, Cavataio MF, Lo Cascio
M, Notarbatolo A. Extreme short bowel syndrome: a case for
reviewing the guidelines for predicting survival. J Pediatr
Gastroenterol Nutr 1993;16:216–19.
112. Klein S. Influence of nutrition support on clinical outcome in
short bowel syndrome and inflammatory bowel disease.
Nutrition 1995;11(2 suppl):233–7.
113. Scolapio JS, Nguyen JH, Steers J, Ukleja A. Success with
intestinal failure: from adaptation to transplantation. Dig Dis
1999;17:107–12.
114. Stanko RT, Nathan G, Mendelow H, Adibi SA. Development
of hepatic cholestasis and fibrosis with massive loss of
intestine supported by prolonged parenteral nutrition.
Gastroenterology 1987;92:197–202.
115. Simmons MG, Georgeson KE, Figueroa R, Mock DL. Liver
failure in parenteral nutrition-dependent children with short
bowel syndrome. Transplant Proc 1996;28:2701.
116. Caniano DA, Starr J, Ginn-Pease ME. Extensive short-bowel
syndrome in neonates: outcomes in the 1980s. Surgery
1989;105:119–24.
117. Meehan JJ, Georgeson KE. Prevention of liver failure in
parenteral nutrition-dependent children with short bowel
syndrome. J Pediatr Surg 1997;32:473–5.
118. Vanderhoof JA, Langnas AN, Pinch LW, Thompson JS,
Kaufman SS. Short bowel syndrome. J Pediatr Gastroenterol
Nutr 1992;14:359–70.
119. Grant D. Intestinal transplantation: 1997 report of the
international registry. Transplantation 1999;67:1061–4.
120. Goulet O, Jan D, Lacaille F, et al. Intestinal transplantation in
children: preliminary experience in Paris. J Parenteral Enteral
Nutr 1999;23:S121–5.
121. Messing B, Colombel JF, Heresbach D, Chazouilleres O,
Galian A. Chronic cholestasis and macronutrient excess in
patients treated with prolonged parenteral nutrition.
Nutrition 1992;8:30–5.
122. Nussbaum MS, Fischer JE. Pathogenesis of hepatic steatosis
during total parenteral nutrition. Surg Annu 1991;23:1–11.
123. Li S, Nussbaum MS, Teague D, Gapen CL, Dayal R, Fischer
JE. Increasing dextrose concentrations in total parenteral
nutrition (TPN) causes alterations in hepatic morphology and
plasma levels of insulin and glucagon in rats. J Surg Res
1988;44:639–48.
124. Bresson JL, Narcy P, Putet G, Ricour C, Sachs C, Rey J.
Energy substrates utilization in infants receiving total
parenteral nutrition with different glucose to fat ratios.
Pediatr Res 1989;25:645–8.
125. Chang S, Silvis SE .  Fatty liver produced by hyper-
alimentation of rates [abstr]. Gastroenterology 1972;62:727.
126. Zagara G, Locati L. Role of total parenteral nutrition in
determining liver insufficiency in patients with cranial
injuries. Glucose vs glucose + lipids. Minerva Anesthesiol
1989;55:509–12.
127. Buzby GP, Mullen JL, Stein TP, Rosato EF. Manipulation of
TPN caloric substrate and fatty infiltration of liver. J Surg Res
1981;31:46–54.
128. Meguid MM, Schimmel E, Johnson WC, et al. Reduced
metabolic complications in total parenteral nutrition: pilot
study using fat to replace one-third of glucose calories. J
Parenteral Enteral Nutr 1982;6:304–7.
129. Meguid MM, Akahoshi MP, Jeffers S, Hayashi RJ, Hammond
WG .  Amelioration of metabolic complications of
conventional total parenteral nutrition. Arch Surg
1984;119:1294–8.
130. Dudrick SJ, Macfadyen BV, Van Buren CT, Ruberg RL,
Maynard AT. Parenteral hyperalimentation. Metabolic
problems and solutions. Ann Surg 1972;176:259–64.
131. Ghadimi H, Abaci F, Kumar S, Rathi M. Biochemical aspects
of intravenous alimentation. Pediatrics 1971;48:955–65.
132. Das JB, Filler RM. Amino acid utilization during total
parenteral nutrition in the surgical neonate. J Pediatr Surg
1973;8:793–9.
133. Beck R. Use of a pediatric parenteral amino acid mixture in a
population of extremely low birth weight neonates: frequency
and spectrum of direct bilirubinemia. Am J Perinatol
1990;7:84–6.
134. Heird WC, Hay W, Helms RA, Storm MC, Kashyap S, Dell
RB. Pediatric parenteral amino acid mixture in low birth
weight infants. Pediatrics 1988;81:41–50.
135. Coran AG, Drongowski RA. Studies on the toxicity and
efficacy of a new amino acid solution in pediatric parenteral
nutrition. J Parenteral Enteral Nutr 1987;11:368–77.
136. Vileisis RA, Inwood RJ, Hunt CE. Prospective controlled
study of parenteral nutrition-associated cholestatic jaundice:
effect of protein intake. J Pediatr 1980;96:893–7.
137. Merritt RJ, Shah PH, Hack SL, et al. Treatment of protracted
diarrhea of infancy. Am J Dis Child 1984;138:770–4.
138. Riely CA, Fine PL, Boyer JL. Progressively rising serum bile
acids. A common effect of parenteral nutrition [abstr].
Gastroenterology 1979;77:A34.
139. Moss RL, Amii LA. New approaches to understanding the
etiology and treatment of total parenteral nutrition-associated
cholestasis. Semin Pediatr Surg 1999;8:140–7.
140. Brown MR, Putnam TC. Cholestasis associated with central
intravenous nutrition in infants. N Y State J Med
1978;78:27–30.
141. Grant JP, Cox CE, Kleinman LM, et al. Serum hepatic
enzyme and bilirubin elevations during parenteral nutrition.
Surg Gynecol Obstet 1977;145:573–80.
142. Zahavi I, Shaffer EA, Gall DG. Total parenteral nutrition
(TPN) associated cholestasis in infant and adult rabbits
[abstr]. Gastroenterology 1982;82:1217.
143. Yousef IM, Tuchweber B, Vonk RJ, Masse D, Audet M, Roy
CC. Lithocholate cholestasis: sulfated glycolithocholate-
induced intrahepatic cholestasis in rats. Gastroenterology
1981;80:233–41.
144. Bucuvalas JC, Goodrich AL, Blitzer BL, Suchy FJ. Amino
acids are potent inhibitors of bile acid uptake by liver plasma
membrane vesicles isolated from suckling rats. Pediatr Res
1985;19:1298–304.
145. Hardwick DF, Applegarth DA, Cockcroft DM, Ross PM,
Calder RJ. Pathogenesis of methionine-induced toxicity.
Metabolism 1970;19:381–91.
146. Preisig R, Rennert O. Biliary transport and cholestatic effects
of amino acids [abstr]. Gastroenterology 1977;73:1240.
147. Perea A, Tuchweber B, Roy CC, Yousef IM. Decreased bile
acid independent flow as a possible cause of amino acids-
induced cholestasis [abstr]. Gastroenterology 1982;82:1258.
148. Perea A, Tuchweber B, Roy CC, Yousef IM. Intrahepatic
cholestasis induced by amino acid solutions for parenteral
nutrition in isolated perfused rat liver [abstr]. Hepatology
1981;1:535.
149. Moss RL, Das JB, Ansari G, Raffensperger JG. Hepatobiliary
dysfunction during total parenteral nutrition is caused by
infusate, not the route of administration. J Pediatr Surg
1993;28:391–7.
150. Sankaran K, Berscheid B, Verma V, Zakhary G, Tan L. An
evaluation of total parenteral nutrition using Viamin and
Aminosyn as protein base in critically ill preterm infants. J
Parenteral Enteral Nutr 1985;9:439–42.
151. Brown MR, Thunberg BG, Golub L, Maniscalco WM, Cox C,
Shapiro DL. Decreased cholestasis with enteral instead of
intravenous protein in the very-low-birth infant. J Pediatr
Gastroenterol Nutr 1989;9:21–7.
152. Anonymous .  Safe practices of parenteral nutrition
formulations. National Advisory Group and practice
207
PHARMACOTHERAPY  Volume 22, Number 2, 2002
guidelines for parenteral nutrition. J Parenteral Enteral Nutr
1998;22:49–66.
153. Thureen PJ, Anderson AH, Baron KA, Melara DL, Hay WW
Jr, Fennessey PV. Protein balance in the first week of life in
ventilated neonates receiving parenteral nutrition. Am J Clin
Nutr 1998;68:1128–35.
154. van Lingen RA, van Goudoever JB, Luijendijk IH,
Wattimena JL, Sauer PJ .  Effects of early amino acid
administration during total parenteral nutrition on protein
metabolism in pre-term infants. Clin Sci 1992;82:199–203.
155. Moss RL, Haynes AL, Pastuszyn A, Glew RH. Methionine
infusion reproduces liver injury of parenteral nutrition
cholestasis. Pediatr Res 1999;45:664–8.
156. Stipanuk MH. Homocysteine, cysteine, and taurine. In: Shils
ME, Olson JA, Shike M, Ross AC, eds. Modern nutrition in
health and disease, 9th ed. Baltimore: Lippincott Williams &
Wilkins, 1999:543–58.
157. Cooper A, Betts JM, Pereira GR, Ziegler MM. Taurine
deficiency in the severe hepatic dysfunction complicating
total parenteral nutrition. J Pediatr Surg 1984;19:462–5.
158. Zlotkin SH, Anderson GH. The development of cystathionase
activity during the first year of life. Pediatr Res 1982;16:65–8.
159. Chesney RW, Helms RA, Christensen M, Budreau AM, Han
X, Sturman JA. The role of taurine in infant nutrition. Adv
Exp Med Biol 1998;442:463–76.
160. Belli DC, Fournier LA, Lepage G, Yousef I, Roy CC. S-
Adenosylmethionine prevents total parenteral nutrition-
induced cholestasis in the rat. J Hepatol 1994;31:18–23.
161. Gerard-Boncompain M, Claudel JP, Gaussorgues P, et al.
Hepatic cytolytic and cholestatic changes related to a change
of lipid emulsions in four long-term parenteral nutrition
patients with short bowel. J Parenteral Enteral Nutr
1992;16:78–83.
162. Whitfield PD, Clayton PT, Muller DPR. Effect of intravenous
lipid emulsions on hepatic cholesterol metabolism. J Pediatr
Gastroenterol Nutr 2000;30:538–46.
163. Doty JE, Pitt HA, Porter-Fink V, DenBesten L. The effects of
intravenous fat and total parenteral nutrition on biliary
physiology. J Parenteral Enteral Nutr 1984;8:263–8.
164. La Scala GC, Le Coultre C, Roche BG, Bugmann P, Belli DC.
The addition of lipids increases the total parenteral nutrition-
associated cholestasis in the rat. Eur J Pediatr Surg
1993;3:224–7.
165. Zaman N, Tam YK, Jewell LD, Coutts RT. Effects of
intravenous lipid as a source of energy in parenteral nutrition
associated hepatic dysfunction and lidocaine elimination: a
study using isolated rat liver perfusion. Biopharm Drug
Dispos 1997;18:803–19.
166. Allardyce DB. Cholestasis caused by lipid emulsions. Surg
Gynecol Obstet 1982;154:641–7.
167. Colomb V, Jobert-Giraud A, Lacaille F, Goulet O, Fournet
JC, Ricour C. Role of lipid emulsions in cholestasis associated
with long-term parenteral nutrition in children. J Parenteral
Enteral Nutr 2000;24:345–50.
168. Richardson TJ, Sgoutas D. Essential fatty acid deficiency in
four adult patients during total parenteral nutrition. Am J
Clin Nutr 1975;28:258–63.
169. Reif S, Tano M, Oliverio R, Young C, Rossi T. Total
parenteral nutrition-induced steatosis: reversal by parenteral
lipid infusions. J Parenteral Enteral Nutr 1991;15:102–4.
170. Tulikoura I, Huikuri K. Morphological fatty changes and
function of the liver, serum free fatty acids, and triglycerides
during parenteral nutrition. Scand J Gastroenterol
1982;17:177–85.
171. Messing B, Latrive JP, Bitoun A, Galian A, Bernier JJ. Is fatty
liver during total parenteral nutrition due to the amount of fat
emulsion energy source? Gastroenterol Clin Biol
1979;3:719–24.
172. Wagner WH, Lowry AC, Silberman H. Similar liver function
abnormalities occur in patients receiving glucose-based and
lipid-based parenteral nutrition. Am J Gastroenterol
1983;78:199–202.
173. Craig RM, Coy D, Green R, Meersman R, Rubin H, Janssen
I. Hepatotoxicity related to total parenteral nutrition:
comparison of low-lipid and lipid-supplemented solutions. J
Crit Care 1994;9:111–13.
174. American Academy of Pediatrics. Use of intravenous fat
emulsions in pediatric patients. Pediatrics 1981;68:738–43.
175. Baldermann H, Wicklmayr M, Rett K, Banholzer P, Dietze G,
Mehnert H. Changes in hepatic morphology during parenteral
nutrition with lipid emulsions containing LCT or MCT/LCT
quantified by ultrasound. J Parenteral Enteral Nutr
1991;15:601–3.
176. Clayton PT, Whitfield P, Iyer K. The role of phytosterols in
the pathogenesis of liver complications of pediatric parenteral
nutrition. Nutrition 1998;14:158–64.
177. Boberg KM, Einarsson K, Bjorkhem I. Apparent lack of
conversion of sitosterol into C24-bile acids in humans. J Lipid
Res 1990;31:1083–8.
178. Iyer KR, Spitz L, Clayton P. New insight into mechanisms of
parenteral nutrition-associated cholestasis: role of plant
sterols. J Pediatr Surg 1998;33:1–6.
179. Clayton PT, Bowron A, Mills KA, Massoud A, Casteels M,
Milla PJ. Phytosterolemia in children with parenteral
nutrition-associated cholestatic liver disease.
Gastroenterology 1993;105:1806–13.
180. Hambidge KM, Sokol RJ, Fidanza SJ, Goodall MA. Plasma
manganese concentrations in infants and children receiving
parenteral nutrition. J Parenteral Enteral Nutr 1989;13:
168–71.
181. Kafrista Y, Fell J, Long S, Bynevelt M, Wendy T, Milla P.
Long term outcome of brain manganese deposition in patients
on home parenteral nutrition. Arch Dis Child 1998;79:263–5.
182. Nagatomo S, Umehara F, Hanada K. Manganese intoxication
during total parenteral nutrition: report of two cases and
review of the literature. J Neurol Sci 1999;162:102–5.
183. Fitzgerald K, Mikalunas V, Rubin H, McCarthy R, Vanagunas
A, Craig RM. Hypermanganesemia in patients receiving total
parenteral nutrition. J Parenteral Enteral Nutr 1999;23:333–6.
184. Reynolds P, Kiely E, Meadows N. Manganese in long term
paediatric parenteral nutrition. Arch Dis Child 1994;71:
527–8.
185. Taylor S, Manara AR. Manganese toxicity in a patient with
cholestasis receiving total parenteral nutrition [letter].
Anaesthesia 1994;49:1013.
186. Fell JM, Reynolds AP, Meadows N, et al. Manganese toxicity
in children receiving long-term parenteral nutrition. Lancet
1996;347:1218–21.
187. Beath SV, Gopalan S, Booth IW. Manganese toxicity and
parenteral nutrition. Lancet 1996;347:1773–4.
188. Plaa GL, De Lamirande E, Lewittes M, Yousef IM. Liver cell
plasma membrane lipids in manganese-bilirubin-induced
intrahepatic cholestasis. Biochem Pharmacol 1982;31:
3698–701.
189. Ayotte P, Plaa GL. Hepatic subcellular distribution of
manganese in manganese and manganese-bilirubin induced
cholestasis. Biochem Pharmacol 1985;34:3857–65.
190. Alastair F, Jawhari I. Manganese toxicity and parenteral
nutrition [letter]. Lancet 1996;347:1774.
191. Jawhari A, Ong C, Wood S, Forbes A. Hypermanganesemia
and TPN: a cause for cholestasis? [abstr]. Gastroenterology
1995;108:A732.
192. Guertin F, Roy CC, Lepage G, et al. Effect of taurine on total
parenteral nutrition-associated cholestasis. J Parenteral
Enteral Nutr 1991;15:247–51.
193. Dorvil NP, Yousef IM, Tuchweber B, Roy CC. Taurine
prevents cholestasis induced by lithocholic acid sulfate in
guinea pigs. Am J Clin Nutr 1983;37:221–32.
194. Guertin F, Roy CC, Lepage G, Yousef I, Tuchweber B. Liver
membrane composition after short-term parenteral nutrition
with and without taurine in guinea pigs: the effect to taurine.
Exp Biol Med 1993;203:418–23.
195. Chipponi JX, Bleier JC, Santi MT, Rudman D. Deficiencies of
essential and conditionally essential nutrients. Am J Clin Nutr
1982;35:1112–16.
196. Zelikovic I, Chesney RW, Friedman AL, Ahlfors CE. Taurine
208
PARENTERAL NUTRITION AND LIVER COMPLICATIONS IN CHILDREN  Btaiche and Khalidi
depletion in very low birth weight infants receiving total
parenteral nutrition: role of renal immaturity. J Pediatr
1990;116:301–6.
197. Geggel HS, Ament ME, Heckenlively JR, Martin DA, Kopple
JD. Nutritional requirement for taurine in patients receiving
long-term parenteral nutrition. N Engl J Med
1985;312:142–6.
198. Vinton NE, Laidlaw SA, Ament ME, Kopple JD. Taurine
concentrations in plasma, blood cells, and urine of children
undergoing long-term total parenteral nutrition. Pediatr Res
1987;21:399–403.
199. Vinton NE, Geggel HS, Amant JR, Heckenlively JR, Martin
DA, Kopple JD. Taurine deficiency in a child on total
parenteral nutrition. Nutr Rev 1985;43:81–3.
200. Cooke RJ, Whitington PF, Kelts D . Effect of taurine
supplementation on hepatic function during short-term
parenteral nutrition in the preterm infant. J Pediatr
Gastroenterol Nutr 1984;3:234–8.
201. Ricour C, Gorski AM, Goulet O, et al. Home parenteral
nutrition in children: 8 years of experience with 112 patients.
Clin Nutr 1990;9:65–71.
202. Okamoto E, Rassin DK, Zucker CL, Salen GS, Heird WC.
Role of taurine in feeding the low-birth-weight infant. J
Pediatr 1984;104:936–40.
203. Thornton L, Griffin E. Evaluation of a taurine containing
amino acid solution in parenteral nutrition. Arch Dis Child
1991;66:21–5.
204. Adamkin DD, Radmacher P, Rosen P. Comparison of a
neonatal versus general-purpose amino acid formulation in
preterm neonates. J Perinatol 1995;15:108–13.
205. Boehm KA, Helms RA, Christensen ML, Storm MC .
Carnitine: a review for the pharmacy clinician. Hosp Pharm
1993;28:843–50.
206. Borum PR, Bennett SG. Carnitine as an essential nutrient. J
Am Coll Nutr 1986;5:177–82.
207. Schmidt-Sommerfeld E, Penn D. Carnitine and parenteral
nutrition of the neonate. Biol Neonate 1990;58(suppl 1):81–8.
208. Palombo JD, Schnure F, Bistrian BR, Buchanan LM,
Blackburn GL. Improvement of liver function tests by
administration of L-carnitine to a carnitine-deficient patient
receiving home parenteral nutrition: a case report. J Parenteral
Enteral Nutr 1987;11:88–92.
209. Worthley LI, Fishlock RC, Snoswell AM .  Carnitine
deficiency with hyperbilirubinemia, generalized skeletal
muscle weakness and reactive hypoglycemia in a patient on
long-term total parenteral nutrition: treatment with
intravenous L-carnitine. J Parenteral Enteral Nutr
1983;7:176–80.
210. Karpati G, Carpenter S, Engel AG, et al. The syndrome of
systemic carnitine deficiency. Clinical, morphologic,
biochemical, and pathophysiologic features. Neurology
1975;25:16–24.
211. Tao RC, Peck GK, Yoshimura NN. Effect of carnitine on liver
fat and nitrogen balance in intravenously fed growing rats. J
Nutr 1981;111:171–7.
212. Sachan DS, Rhew TH, Ruark RA. Ameliorating effects of
carnitine and its precursors on alcohol-induced fatty liver. Am
J Clin Nutr 1984;39:738–44.
213. Dahlstrom KA, Ament ME, Moukarzel AA, Vinton NE,
Cederblad G. Low blood and plasma carnitine levels in
children receiving long-term parenteral nutrition. J Pediatr
Gastroenterol Nutr 1990;11:375–9.
214. Schiff D, Chan G, Secombe D, Hohn P. Plasma carnitine
levels during intravenous feeding of the neonate. J Pediatr
1979;95:1043–6.
215. Penn D, Schmidt-Sommerfeld E, Wolf H .  Carnitine
deficiency in premature infants receiving total parenteral
nutrition. Early Hum Dev 1980;4:23–34.
216. Moukarzel AA, Dahlstrom KA, Buchman AL, Ament ME.
Carnitine status of children receiving long-term total
parenteral nutrition: a longitudinal prospective study. J
Pediatr 1992;120:759–62.
217. Penn D, Schmidt-Sommerfeld E, Pascu F. Decreased tissue
carnitine concentrations in newborn infants receiving total
parenteral nutrition. J Pediatr 1981;98:976–8.
218. Helms RA, Mauer EC, Hay WW, Christensen ML, Storm
MC. Effect of intravenous L-carnitine on growth parameters
and fat metabolism during parenteral nutrition in neonates. J
Parenteral Enteral Nutr 1990;14:448–53.
219. Bonner CM, DeBrie KL, Hug G, Landrigan E, Taylor BJ.
Effects of L-carnitine supplementation on fat metabolism and
nutrition in premature infants. J Pediatr 1995;126:287–92.
220. Schmidt-Sommerfeld E, Penn D, Wolf H .  Carnitine
deficiency in premature infants receiving total parenteral
nutrition: effect of L-carnitine supplementation. J Pediatr
1983;102:931–5.
221. Bowyer BA, Miles JM, Haymond MW, Fleming CR. L-
Carnitine therapy in home parenteral nutrition patients with
abnormal liver tests and low plasma carnitine concentrations.
Gastroenterology 1988;94:434–8.
222. Borum PR. Is L-carnitine stable in parenteral nutrition
solutions prepared for preterm neonates? Neonatal Intensive
Care 1993;6:30–2.
223. Bullock L, Fitzgerald JF, Walter WV. Emulsion stability in
total nutrient admixtures containing a pediatric amino acid
formulation. J Parenteral Enteral Nutr 1992;16:64–8.
224. Tibboel D, Delemarre FMCH, Przyrembel H, Bos AP,
Affourtit MJ, Molenaar JC. Carnitine deficiency in surgical
neonates receiving total parenteral nutrition. J Pediatr Surg
1990;25:418–21.
225. Haskel Y, Udassin R, Freund HR, Zhang JM, Hanani M.
Liquid enteral diets induce bacterial translocation by
increasing cecal flora without changing intestinal motility. J
Parenteral Enteral Nutr 2001;25:60–4.
226. Takagi K, Yamamori H, Toyoda Y, Nakajima N, Tashiro T.
Modulating effects of the feeding route on stress response and
endotoxin translocation in severely stressed patients receiving
thoracic esophagectomy. Nutrition 2000;16:355–60.
227. Aarsland A, Chinkes D, Wolfe RR. Hepatic and whole-body
fat synthesis in humans during carbohydrate overfeeding. Am
J Clin Nutr 1997;65:1774–82.
228. Chascione C, Elwyn DH, Davila M, Gil KM, Askanazi J,
Kinney JM. Effect of carbohydrate on de novo lipogenesis in
human adipose tissue. Am J Physiol 1987;253:E664–9.
229. Collier S, Crough J, Hendricks K, Caballero B. Use of
parenteral nutrition in infants less than 6 months of age. Nutr
Clin Pract 1994;9:65–8.
230. Maini B, Blackburn GL, Bistrian BR, et al .  Cyclic
hyperalimentation: an optimal technique for preservation of
visceral proteins. J Surg Res 1976;20:515–25.
231. Takehara H, Hino M, Kameoka K, Komi N. A new method of
total parenteral nutrition for surgical neonates: is it possible
that cyclic TPN prevents intrahepatic cholestasis?  Tokushima
J Exp Med 1990;37:97–102.
232. Ternullo SR, Burckart GJ .  Experience with cyclic
hyperalimentation in infants [abstr]. J Parenteral Enteral Nutr
1979;3:516.
233. Pollak A, Cowett RM, Schwartz R, et al. Glucose disposal in
low-birth-weight infants during steady-state hyperglycemia:
effects of exogenous insulin administration. Pediatrics
1978;61:546–9.
234. Cornblath M, Hawdon JM, Williams AF, et al. Controversies
regarding the definition of neonatal hypoglycemia: suggested
operational thresholds. Pediatrics 2000;105:1141–5.
235. Frenkiel PG, Lee DWT, Cohen H, et al. The effect of diet on
bile kinetics and biliary lipid secretion in gallstone patients
treated with ursodeoxycholic acid. Am J Clin Nutr
1986;43:239–50.
236. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the
treatment of cholesterol cholelithiasis (part I). Dig Dis Sci
1982;27:737–61.
237. Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary
disease. Am J Med 2000;108:481–6.
238. Schwarzenberg SJ, Bundy M. Ursodeoxycholic acid modifies
gut-derived endotoxemia in neonatal rats. Pediatr Res
1994;35:214–17.
209
PHARMACOTHERAPY  Volume 22, Number 2, 2002
239. Hori Y, Ohyanagi H. Protective effect of the intravenous
administration of ursodeoxycholic acid against endotoxemia
in rats with obstructive jaundice. Surg Today 1997;27:140–4.
240. Stiehl A, Czygan P, Kommerell B, Weis HJ, Holtermuller KH.
Ursodeoxycholic acid versus chenodeoxycholic acid.
Comparison of their effects on bile acid and bile lipid
composition in patients with cholesterol gallstones.
Gastroenterology 1978;75:1016–20.
241. Beau P, Labat-Labourdette J, Ingrand P, Beauchant M. Is
ursodeoxycholic acid an effective therapy for total parenteral
nutrition-related liver disease?  J Hepatol 1994;20:240–4.
242. Lindor KD, Burnes J. Ursodeoxycholic acid for the treatment
of home parenteral nutrition-associated cholestasis. A case
report. Gastroenterology 1991;101:250–3.
243. Bateson MC, Ross PE, Diffey BL. Ursodeoxycholic acid in
primary biliary cirrhosis. Lancet 1989;1:898–9.
244. Fein BI, Holt PR. Hepatobiliary complications of total
parenteral nutrition. J Clin Gastroenterol 1994;18:62–6.
245. Roda A, Roda E, Marchi E, et al. Improved intestinal
absorption of an enteric-coated sodium ursodeoxycholate
formulation. Pharm Res 1994;11:642–7.
246. Novartis. Actigall (ursodiol) package insert. East Hanover, NJ;
1997.
247. Galabert C, Montet JC, Lengrand D, et al. Effects of
ursodeoxycholic acid on liver function in patients with cystic
fibrosis and chronic cholestasis. J Pediatr 1992;121:138–41.
248. Taketomo CK, Hodding JH, Kraus DM, eds. Ursodiol.
Pediatric dosage handbook, 7th ed. Hudson, OH: Lexi-Comp
Inc., 2000:965–6.
249. Sitzmann JV, Pitt HA, Steinborn PA, Pasha ZR, Sanders RC.
Cholecystokinin prevents parenteral nutrition induced biliary
sludge in humans. Surg Gynecol Obstet 1990;170:25–31.
250. Teitelbaum DH, Han-Markey T, Drongowski R, Coran AG,
Bayar B, Geiger JD. Use of cholecystokinin to prevent the
development of parenteral nutrition-associated cholestasis. J
Parenteral Enteral Nutr 1997;20:100–3.
251. Innis SM. Effect of cholecystokinin-octapeptide on total
parenteral nutrition-induced changes in hepatic bile secretion
and composition in the rat. J Pediatr Gastroenterol Nutr
1986;5:793–8.
252. Doty JE, Pitt HA, Porter-Fink V, DenBesten L .
Cholecystokinin prophylaxis of parenteral nutrition-induced
gallbladder disease. Ann Surg 1985;201:76–80.
253. Curran TJ, Uzoaru I, Das JB, Ansari G, Raffensperger JG.
The effect of cholecystokinin-octapeptide on the hepatobiliary
dysfunction caused by total parenteral nutrition. J Pediatr
Surg 1995;30:242–7.
254. Dawes LG, Muldoon JP, Greiner MA, Bertolotti M .
Cholecystokinin increases bile acid synthesis with total
parenteral nutrition but does not prevent stone formation. J
Surg Res 1997;67:84–9.
255. Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment
strategies for small bowel bacterial overgrowth in short bowel
syndrome. J Pediatr Gastroenterol Nutr 1998;27:155–60.
256. Capron JP, Gineston JL, Herve MA, Braillon A .
Metronidazole in prevention of cholestasis associated with
total parenteral nutrition. Lancet 1983;1:446–7.
257. Kubota A, Okada A, Imura K, et al .  The effect of
metronidazole on TPN-associated liver dysfunction in
neonates. J Pediatr Surg 1990;6:618–21.
258. Lambert JR, Thomas SM. Metronidazole prevention of serum
liver enzyme abnormalities during total parenteral nutrition. J
Parenteral Enteral Nutr 1985;9:501–3.
259. Freund HR, Muggia-Sullam M, LaFrance R, Enbrione EB,
Popp MB, Bjornson HS. A possible beneficial effect of
metronidazole in reducing TPN-associated liver function
derangements. J Surg Res 1985;38:356–63.
260. Lichtman SN, Keku J, Schwab JH, Sartor RB. Hepatic injury
associated with small bowel bacterial overgrowth in rats is
prevented by metronidazole and tetracycline.
Gastroenterology 1991;100:513–19.
261. Spurr SG, Grylack LJ, Mehta NR. Hyperalimentation-
associated neonatal cholestasis: effect of oral gentamicin. J
Parenteral Enteral Nutr 1989;13:633–6.
262. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after
intestinal bypass. Prevention and reversal by metronidazole,
irrespective of protein-calorie malnutrition. Gastroenterology
1982;82:535–48.
263. Powell-Jackson PR, Maudgal DP, Sharp D, Goldie A,
Maxwell JD. Intestinal bacterial metabolism of protein and
bile acids: role in pathogenesis of hepatic disease after jejuno-
ileal bypass surgery. Br J Surg 1979;66:772–5.
264. Elleby H, Solhaug JH. Metronidazole, cholestasis and total
parenteral nutrition [letter]. Lancet 1983;1:1161.
265. Broitman SA, Gottlieb LS, Zamcheck N. Influence of
neomycin and ingested endotoxin in the pathogenesis of
choline deficiency cirrhosis in the adult rat. J Exp Med
1964;119:633–42.
266. Srimal S, Surolia N, Balasubramanian S, Surolia A. Titration
calorimetric studies to elucidate the specificity of the
interactions of polymyxin B with lipopolysaccharides and
lipid A. Biochem J 1996;315:679–86.
267. South M, King A. Parenteral nutrition-associated cholestasis:
recovery following phenobarbitone. J Parenteral Enteral Nutr
1987;11:208–9.
268. Gleghorn EE, Merritt RJ, Subramanian N, Ramos A.
Phenobarbital does not prevent total parenteral nutrition-
associated cholestasis in noninfected neonates. J Parenteral
Enteral Nutr 1986;10:282–3.
269. Nemeth A, Wikstrom SA, Strandvik B. Phenobarbital can
aggravate a cholestatic bile acid pattern in infants with
obstructive cholangiopathy. J Pediatr Gastroenterol Nutr
1990;10:290–7.
270. Bachs L, Pares A, Elena M, Piera C .  Comparison of
rifampicin with phenobarbitone for treatment of pruritus in
biliary cirrhosis. Lancet 1989;1:574–6.
271. Cynamon HA, Andres JM, Iafrate RP. Rifampin relieves
pruritus in children with cholestatic liver disease.
Gastroenterology 1990;98:1013–16.
272. Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Karrer
FM. Use of rifampin for severe pruritus in children with
chronic cholestasis. J Pediatr Gastroenterol Nutr
1999;29:442–7.
273. Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-
term rifampicin administration in primary biliary cirrhosis.
Gastroenterology 1992;102:2077–80.
274. Galeazzi R, Lorenzini I, Orlandi F. Rifampicin-induced
elevation of serum bile acids in man. Dig Dis Sci
1980;25:108–12.
275. Bergasa NV, Jones EA. The pruritus of cholestasis. Semin
Liver Dis 1993;13:319–27.
276. Datta DV, Sherlock S. Cholestyramine for long term relief of
the pruritus complicating intrahepatic cholestasis.
Gastroenterology 1966;50:323–32.
277. Hofmann AF, Poley JR. Cholestyramine treatment of diarrhea
associated with ileal resection. N Engl J Med
1969;281:397–402.
278. Nolan JP, Ali MV. Effect of cholestyramine on endotoxin
toxicity and absorption. Dig Dis 1972;17:161–6.
279. Houdijk AP, Boermeester MA, Wesdorp RI, Hack CE, Van
Leeuwen PA. Tumor necrosis factor unresponsiveness after
surgery in bile duct-ligated rats. Am J Physiol
1996;271:G980–6.
280. Hofmann AF, Poley R. Role of bile acid malabsorption in
pathogenesis of diarrhea and steatorrhea in patients with ileal
resection. Gastroenterology 1972;62:918–34.
281. Fromm H, Malavolti M. Bile acid-induced diarrhea. Clin
Gastroenterol 1986;15:567–82.
282. Khandelwal M, Malet PF .  Pruritus associated with
cholestasis. Dig Dis Sci 1994;39:1–8.
283. Taketomo CK, Hodding JH, Kraus DM, eds. Cholestyramine
resin. Pediatric dosage handbook, 7th ed. Hudson, OH: Lexi-
Comp Inc., 2000:219–20.
284. Rust C, Sauter GH, Oswald M, et al. Effect of cholestyramine
on bile acid pattern and synthesis during administration of
ursodeoxycholic acid in man. Eur J Clin Invest
210
PARENTERAL NUTRITION AND LIVER COMPLICATIONS IN CHILDREN  Btaiche and Khalidi
2000;30:135–9.
285. Eon Labs Manufacturing .  Cholestyramine for oral
suspension, USP light package insert. Laurelton, NY; 2000.
286. Gilroy R, Sudan D. Liver and small bowel transplantation:
therapeutic alternatives for the treatment of liver disease and
intestinal failure. Semin Liver Dis 2000;20:437–50.
287. Brook G. Quality of life issues; parenteral nutrition to small
bowel transplantation—a review. Nutrition 1998;14:813–16.
288. DiMartini A, Rovera GM, Graham TO, et al. Quality of life
after intestinal transplantation and among home parenteral
nutrition patients. J Parenteral Enteral Nutr 1998;22:357–62.
289. Howard L, Malone M. Current status of home parenteral
nutrition in the United States. Transplant Proc 1996;28:
2691–5.
290. Horslen SP, Kaufman SS, Sudan DL, Fox IJ, Shaw BW,
Langnas AN. Isolated liver transplantation in infants with
total parenteral nutrition-associated end-stage liver disease.
Transplant Proc 2000;32:1241.
211
